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Zusammenfassung 
 
Hintergrund 
Die derzeitigen Entwicklungen hin zu einer alternden Bevölkerung und ungünstigen 
Lebensstilveränderungen haben dazu beigetragen, dass immer mehr Menschen immer länger mit Typ 2 
Diabetes und den damit einhergehenden Folgen von Multimorbidität leben. Verschiedene mikro- und 
makrovaskuläre Komplikationen sind als bedeutende Ursache der gesteigerten Morbidität und 
Mortalität bekannt und stellen eine signifikante ökonomische Belastung dar. Mathematische 
Diabetesmodelle bieten ein nützliches Instrument, um den Krankheitsprozess zu simulieren, klinisch 
relevante Ereignisse und Kosten vorherzusagen und Entscheidungsträger somit in der Abschätzung 
möglicher Folgen neuer Therapie- und Managementansätze für Patienten zu unterstützen. Trotz des 
internationalen Einsatzes, gibt es derzeit noch kein basierend auf individuellen Patientendaten 
angepasstes Diabetesmodell für den deutschen Kontext. Zu diesem Zweck und um detailliertere 
Kosteninformationen zu ermitteln, stellen sogenannte „Real World“-Daten eine der umfangreichsten 
und bedeutendsten Datenquellen dar. In diesem Zusammenhang müssen geeignete methodische Ansätze 
entwickelt werden, um auf Basis dieser Daten spezifische Modellparameter valide schätzen zu können.  
 
Ziele 
Diese Dissertation mit ihren Teiluntersuchungen verfolgt eine systematische Analyse von Routinedaten 
der größten bundesweiten Krankenkasse mit der übergeordneten Leitidee möglichst umfangreiche und 
differenzierte Informationen zu den direkten Kosten des Typ 2 Diabetes und seiner assoziierten 
Folgekomplikationen für Diabetesmodelle bereitzustellen. Damit sollen insbesondere zwei Ziele 
erreicht werden: Zum einen geht es darum, aktuelle empirische Evidenz zu den ökonomischen Folgen 
von Typ 2 Diabetes-Komplikationen zu generieren. Zum anderen sollen konzeptionelle und 
methodische Ansätze erarbeitet werden, die einen Umgang mit Validitätsproblemen in 
Krankenkassendaten erlauben und der Komplexität des Krankheitsbildes durch Multimorbidität 
Rechnung tragen. Die erste Studie liefert zu diesem Zweck detaillierte Kostenschätzer für die 
Erstdiagnose verschiedener Typ 2 Diabetes-Komplikationen im Längsschnitt. Die zweite Studie umfasst 
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vor allem eine fundierte methodische Vertiefung verschiedener Strategien, um die ökonomischen 
Auswirkungen mehrerer gleichzeitig bestehender Typ 2 Diabetes-Komplikationen und ihre 
Interaktionensmuster zu untersuchen.  
 
Methoden 
Diese Dissertation basiert auf bundesweiten Patientendaten von 316.220 (über 18 Jahre alten) 
Versicherten mit Typ 2 Diabetes der Techniker Krankenkasse im Basisjahr 2012 und 3-Jahres-Follow-
up von 2013-2015. Alle diabetesassoziierten Folgekomplikationen, die typischerweise in 
internationalen Diabetesmodellen beschrieben werden, wurden basierend auf ambulanten und 
stationären Diagnosedaten sowie abgerechneten Leistungen identifiziert. Hierzu standen quartalsweise 
Beobachtungen pro Kalenderjahr und Patient zur Verfügung. Direkte Kosten (Bezugsjahr 2015) 
beinhalten Kosten für ambulante und stationäre Leistungen, Arzneimittel, Rehabilitation und Heil- und 
Hilfsmittel. Als Erweiterung zu gängigen generalisierten linearen Modellen (GLM) wurden Generalized 
Estimating Equations (GEE)-Modelle verwendet, um wiederholte Beobachtungen am selben Patienten 
zu berücksichtigen. Aufgrund der hinreichend großen Population und dem niedrigen Anteil an 
Nullkosten wurde im Basisfall jeweils eine Normalverteilung der Kosten angenommen. In der ersten 
Studie wurde ein GEE-Modell entwickelt, welches die Gesamtkosten für einen Patienten mit Typ 2 
Diabetes pro Quartal vorhersagt, adjustiert nach Altersgruppen, Geschlecht, Auftreten verschiedener 
Komplikationen, Vorgeschichte der Komplikationen im Basisjahr und Tod (aus anderen Gründen als 
den berücksichtigten Komplikationen). Zusätzlich zur Unterscheidung zwischen inzidenten und 
prävalenten Komplikationen, lag ein weiterer Schwerpunkt auf der Differenzierung von nichttödlich 
oder tödlich verlaufenden akuten makrovaskulären Ereignissen, sowie auf der Quantifizierung der 
Kosten sowohl im Quartal des Ereignisses/Krankheitsbeginns als auch in den Folgequartalen unter der 
Berücksichtigung von alters- und geschlechtsspezifischen Interaktionen. Darauf aufbauend untersucht 
die zweite Studie vier unterschiedlich granulare Strategien, mit dem Ziel die ökonomischen 
Auswirkungen der diabetesassoziierten Multimorbidität zu untersuchen, angefangen mit der groben 
Berücksichtigung der Anzahl prävalenter Komplikationen, über das gemeinsame Bestehen von mikro- 
und makrovaskulären Komplikationen, bis hin zur Berücksichtigung spezifischer Interaktionen und dem 
Zusammenfassung
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Auftreten inzidenter Komplikationen neben bereits bestehenden chronischen Komplikationen. Hierfür 
wurden GEE-Modelle entwickelt und auf die jährlichen Beobachtungsdaten angewandt, um die 
statistische Power zu erhöhen.  
 
Ergebnisse 
Der additive Ansatz (unter Berücksichtigung eines GEE-Models mit Normalverteilung) zeigte einen 
besseren Modellfit verglichen mit einem multiplikativen Modell basierend auf einem Gamma-GEE-
Modell. Ausgehend von dem Beispiel eines 60 bis 69 Jahre alten Mannes, wurden in der ersten Studie 
folgende Gesamtkosten für das erste Diagnosequartal der Komplikationen ermittelt: diabetischer Fuß 
1.293€, Amputation 14.284€, Retinopathie 671€, Erblindung 2.933€, Nephropathie 3.353€, chronisches 
Nierenversagen 22.691€, nichttödlicher Schlaganfall 9.769€, tödlicher Schlaganfall 11.176€, 
nichttödlicher Myokardinfarkt/Herzstillstand 8.035€, tödlicher Myokardinfarkt/Herzstillstand 8.700€, 
nichttödliche (andere) ischemische Herzkrankheit (IHK) 6.548€, tödliche IHK 20.842€, chronische 
Herzinsuffizienz 3.912€, and Angina pectoris 2.695€. In den Folgequartalen reichten die Kosten von 
681€ für Retinopathie bis zu 6.130€ für chronisches Nierenversagen. Männer und Frauen 
unterschiedlicher Altersgruppen unterschieden sich hinsichtlich ihrer Kosten für Komplikationen. Die 
zweite Studie konnte darüber hinaus zeigen, dass die gestiegene Anzahl von aufgetretenen 
Komplikationen mit signifikant höheren jährlichen Gesamtkosten pro Patient assoziiert ist. Weitere 
Untersuchungen haben ergeben, dass makrovaskuläre Komplikationen (z.B. chronische 
Herzinsuffizienz) und kostenintensive Komplikationen (z.B. chronisches Nierenversagen, Amputation) 
zu signifikant positiven Interaktionseffekten hinsichtlich der jährlichen Gesamtkosten führen, während 
die Beobachtung früher mikrovaskulärer Veränderungen (z.B. Retinopathie) zu negativen 
Interaktionseffekten führen kann. Die chronologische Abfolge des Komplikationsgeschehens stellte sich 
ebenfalls als wichtiger Einflussfaktor in der Schätzung von Interaktionseffekten heraus.   
Zusammenfassung
9
 
103 
 
10 
Schlussfolgerungen 
Die Ergebnisse dieser Dissertation haben wichtige Implikationen für verschiedene Akteure im 
Gesundheitswesen. Für den wissenschaftlichen Bereich, insbesondere für die Diabetesmodellierung, 
liefern die Studien nicht nur umfangreiche empirische Kostenschätzer zur Parametrisierung eines auf 
den deutschen Kontext adaptierten Typ 2-Diabetesmodells, sondern liefern auch wichtige 
konzeptionelle und strategische Ansätze zur Analyse von großen Krankenkassenpopulationen. Die 
empirische Fundierung dieser Arbeit sowie die methodische Aufbereitung des Themas können zu einer 
höheren Genauigkeit von zukünftigen Kosten-Effektivitäts-Analysen beitragen, in der insbesondere 
Multimorbiditätsaspekte und Interaktionsmuster stärker berücksichtigt werden. Aus einer 
gesundheitspolitischen oder Krankenkassen-Perspektive, liefern die Studien wertvolle Informationen 
zur Unterstützung einer optimalen Ressourcenallokation zwischen verschiedenen Präventions- und 
Behandlungsprogrammen für Patienten mit Typ 2 Diabetes. Zudem unterstreichen die 
Forschungsergebnisse die Forderung nach ganzheitlich integrierten Ansätzen, welche vorbestehende 
oder begleitende Erkrankungen stärker berücksichtigen. Aus klinischer Perspektive schärfen diese 
umfassenden Ergebnisse das Bewusstsein für die derzeitige ökonomische Belastung durch Typ 2 
Diabetes-assoziierte Komplikationen. Weitere Beobachtungsstudien werden benötigt, um ein 
vollständigeres Verständnis von den zu Grunde liegenden gemeinsamen pathologischen Mechanismen 
des Typ 2 Diabetes und seiner Komplikationen zu erhalten. Real World-Daten, zu denen die 
Routinedaten der gesetzlichen Krankenversicherung gehören, können klinische Studiendaten sinnvoll 
ergänzen. Um den Mehrwert dieser Daten in der Zukunft zu steigern, gilt es die im Rahmen dieser 
Studien aufgezeigten Validierungslücken weiter zu untersuchen und so weit wie möglich zu schließen.  
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Abstract  
 
Background 
In the context of an ageing population and unfavorable trends in lifestyle factors, more people are living 
longer with type 2 diabetes and associated multimorbidity. Various micro- and macrovascular 
complications have been shown to contribute substantially to the morbidity, mortality and economic 
burden of type 2 diabetes. Mathematical models of diabetes provide a useful tool that can help to 
simulate the disease process, predict clinical and economic outcomes, and thereby assist decision makers 
in assessing the possible impact of a range of new diabetes interventions. At present, internationally 
available type 2 diabetes models are not well adapted to German patient level data. To achieve this, and 
especially to obtain detailed cost information, real-world health insurance data are one of the most 
powerful data sources to be used. However, methodological approaches to map these data into model 
parameters have to be further developed. 
 
Objectives 
This dissertation with its sub-studies seeks to systematically analyze routine data of a large statutory 
health insurance fund to inform diabetes simulation models on the direct costs of type 2 diabetes-related 
complications. In particular, this work has the two-fold aims, to provide new empirical evidence on 
diabetes-related costs for Germany, and to develop conceptual and methodological approaches that are 
capable of dealing with validity issues of routine data and the complexity due to multimorbidity in the 
diabetes population. In this context, the first study provides detailed estimates on the longitudinal costs 
associated with the diagnosis of various complications. The second study is more focused on pursuing 
the methodological depth in this research by exploring different strategies that address the economic 
impact of multiple type 2 diabetes-related complications and their interactions. In addition, this study 
describes important interaction patterns of co-occurring complications. 
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Methods 
This dissertation is based on nationwide claims data of 316,220 (over 18 years-old) type 2 diabetes 
patients who were insured by the Techniker Krankenkasse in the baseline year 2012 and the 3-year 
follow-up period from 2013-2015. All diabetes-related complications that are typically included in 
international diabetes models were identified based on outpatient and inpatient diagnoses and 
procedures. Quarterly observations were available for each year and patient. Direct health care costs (in 
2015 euros) include costs for outpatient and inpatient care, medication, rehabilitation, and the provision 
of aids and appliances. Generalized estimating equations (GEE) models are used to account for repeated 
observations per patient as an extension to traditional generalized linear models. As the base case, a 
normal distribution of the mean costs was assumed, given the large population size and small proportion 
of zero costs. In particular, in the first study, a GEE model predicting quarterly total costs was developed, 
adjusted for the age group, sex, occurrence of different (incident) complications, history of prevalent 
complications at baseline, and death for other reasons. In addition to distinguishing incident/prevalent 
complications, special emphasis was given to differentiate between fatal/nonfatal acute macrovascular 
events, to quantify costs at the quarter of event/onset and in subsequent quarters, and to consider 
interactions of complications with age or sex. Building on this, the second study explores four strategies 
of different granularity to assess the economic impact of diabetes-related multimorbidity, including the 
number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease–
disease interactions of prevalent complications, and interactions of incident on top of already prevalent 
complications. For this, different GEE models were developed and applied to the annual observations 
to increase the statistical power.  
 
Results 
The additive approach (using a GEE model with a normal distribution) showed a better model fit 
compared to a multiplicative approach with a gamma-based GEE model. Using the example of a 60-69 
year old man, the first study estimated the following total costs in the quarter of first diagnosis of the 
complication: diabetic foot €1,293, amputation €14,284, retinopathy €671, blindness €2,933, 
nephropathy €3,353, end-stage renal disease (ESRD) €22,691, nonfatal stroke €9,769, fatal stroke 
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€11,176, nonfatal myocardial infarction/cardiac arrest (MI/CA) €8,035, fatal MI/CA €8,700, nonfatal 
other ischemic heart disease (IHD) €6,548, fatal IHD €20,842, chronic heart failure €3,912, and angina 
pectoris €2,695. In the subsequent quarters, costs ranged from €681 for retinopathy to €6,130 for ESRD. 
Men and women from different age groups differed in their costs for complications. In addition, the 
second study showed that the increased number of complications is significantly associated with higher 
annual total costs per patient. Further assessment of interactions revealed that macrovascular 
complications (e.g., CHF) and high cost complications (e.g., ESRD, amputation) lead to significant 
positive interactions on annual costs, whereas early microvascular complications (e.g., retinopathy) 
caused negative interactions. The chronology of the onset of these complications turned out to have an 
additional impact on the cost estimates of interactions. 
 
Conclusions 
The results of this dissertation have important implications for different healthcare stakeholders. From 
a modeler’s or researcher’s perspective, the two studies provide comprehensive empirical estimates for 
the economic parametrization of type 2 diabetes models, especially for Germany, as well as 
methodological approaches for the claims-based analysis of large diabetes populations. These concepts 
will also help to further improve the accuracy of international cost-effectiveness evaluations by 
addressing multimorbidity, and especially interaction patterns. From a policy or SHI perspective, the 
studies provide valuable information to support the optimal resource allocation across different 
intervention programs for the prevention and management of type 2 diabetes complications. In addition, 
the results encourage a more integrated approach that takes better account of preexisting or co-occurring 
conditions. From a clinician’s perspective, the empirical findings may increase the awareness of the 
economic burden of complications in patients with type 2 diabetes. Further observational studies are 
still needed to gain a more complete understanding of the multiple shared pathogenic mechanisms of 
diabetes and its complications. Real world data, including health insurance claims data, can be used to 
successfully complement clinical data. To increase the added value of these data, remaining validation 
gaps need to be further examined and closed.   
Abstract
13
 
103 
 
14 
 
 
 
 
 
 
 
 
Preface 
“Everyone dealing with health care today knows there is an elephant in the room, impossible to miss 
but frequently ignored—the cost of diabetes care.” 
Matthew C. Riddle  
 
This metaphor symbolizes diabetes as a major challenge, standing in the way of patients and their 
families every day and putting healthcare providers, payers and regulators under increasing pressure [1]. 
What is also known as the burden of disease (Introductory section 1.1), does not appear overnight, but 
rather develops over a longer period of time. This also means to think of diabetes (particularly type 2 
diabetes) as a continuum of disease that may begin with overweight and other risk factors, then becomes 
prediabetes, then diabetes, and ultimately leads to the progression of a wide range of diabetic 
complications (section 1.2). Diabetes simulation models strive to account for this dynamic disease 
process, multiple complications, and related health care costs in health economic evaluations of new 
diabetes interventions and programs (section 1.4). Since the validity of a model highly depends on the 
inputs, data sources and methods should be used carefully to inform such health economic models 
(section 1.3). The following thesis, with its sub-studies, has been written in light of this context. Primary 
aim was to use real-world data of a large health insurance fund to contribute new empirical evidence 
and methodological perspectives on the evaluation of costs of complications in patients with type 2 
diabetes for the economic parametrization of diabetes models.  
Preface
14
 
103 
 
15 
1 Introductory summary and motivation 
1.1 Identifying type 2 diabetes and its complications as a high burden disease and research 
priority  
“Diabetes, long thought of as a Cinderella disease, has become a major challenge of the 21st century”  
Paul Zimmet [2] 
 
The burden of diabetes can be viewed from at least three perspectives: morbidity (including health-
related quality of life (HRQoL)), mortality, and economic impact. In short, this section aims to provide 
an overview of the burden of diabetes in order to understand the various demands on diabetes research, 
the central role of complications and the confluence of these perspectives in the examination of the 
economy of diabetes.  
In terms of morbidity at a population level, an increasing global trend in the prevalence of type 2 diabetes 
is expected due to demographic changes and shifts in population dietary patterns and physical inactivity 
(e.g., increases in diabetes cases in youth, continued rise of the numbers of older patients with diabetes) 
[3-5]. In Germany, the prevalence of known type 2 diabetes was estimated to be 7–8% of the adult 
population in 2011, which is slightly above the global average [6-8]. As a serious chronic disease, 
diabetes also belongs to the top five causes of long-term disability [9]. A closer look at the individual 
patient level reveals that patients often make substantial changes to their lifestyle behavior and in their 
physical and psychological health [10]. Consequently, one of the main causes of the severity of diabetes 
is the development of various complications and (multi-)morbidity patterns that vary widely in their 
manifestations [11]. Considering these factors, German cohort studies showed a faster decline in the 
HRQoL score of patients with diabetes (compared to people without diabetes) and especially those with 
multiple complications [12, 13].  
As on the second point (burden of mortality), it has to be considered that better glucose-lowering drugs, 
structured education programs and improved prognosis of other chronic diseases (e.g., myocardial 
infarction, renal insufficiency) have contributed to life expectancy improvements in diabetes patients 
[14, 15]. Although diabetes is not a leading cause of death in Germany, the diabetes-related excess 
mortality in people >40 years of age was estimated to be 21% (all diabetes types) and 16% (type 2) in 
2010, which is above what was measured in international studies (8%) [16, 17]. Again, beyond different 
Introductory summary and motivation
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data sources and methods, diabetes complications turned out to play an important and challenging role 
in estimating the diabetes-related mortality, because most people die of diabetes complications and 
comorbidities and not of diabetes itself.  
Finally, the economic burden of type 2 diabetes (that is typically measured by cost of illness studies) is 
mainly a result of the other two points integrated in a complex national health care and legislative 
system. Although there is literature on this field, it is important to note that cost of illness studies are 
systematically different from other study designs due to their characteristic interest to quantify the total 
(excess) costs attributable to the disease rather than its specific components. Since 1999, there are few 
studies on the societal total costs of diabetes (including direct and indirect costs) extrapolated to the 
entire German population [18, 19]. The Costs of Diabetes Mellitus (CoDiM) study reports a rise in the 
direct cost burden of diabetes from €15 billion in 2001 to €21 billion in 2009 based on a retrospective 
bottom-up analysis of ~30,000 insured diabetes patients (all types) and matched controls in the Hessian 
AOK [20-22]. A recent study by a German group used a top-down approach to look at the global 
economic burden of diabetes in 180 countries in 2015 [23]. They estimated direct and indirect costs of 
all diabetes types of approximately US$38 and 17 billion for Germany, compared to a global burden of 
US$1.3 trillion that was expected to increase in the future [24]. Other population-based German studies 
without extrapolation report excess costs of €3,625 (59% indirect costs) per patient with type 2 diabetes 
[25]. Moreover, these studies indicate that, apart from a long duration of diabetes and treatment with 
insulin, complications play a significant role in the assessment of the economic burden [25-27]. 
What this thesis is able to add to the research, particularly on the economic burden of type 2 diabetes, 
is carving out the detailed economic impact of complications in patients with type 2 diabetes, specified 
morbidity patterns and risk of mortality. This includes (1) discriminating type 2 from other diabetes 
types, (2) effectively analyzing longitudinal data rather than to conduct serial cross-sectional studies, 
(3) not excluding patients who died in the follow-up (e.g., due to fatal diabetes complications), and (4) 
providing robust cost estimates based on a larger population dataset.   
Introductory summary and motivation
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1.2 Focusing on the costs of diabetes-related complications and associated multimorbidity 
“1+1+1 = Multimorbidity is more than the addition of monopathologies” Cornel C. Sieber [28] 
 
Type 2 diabetes is a multisystem chronic disease that is associated with a wide range of complications 
that share similar risk factors [29-31]. Traditionally, complications are divided into those with primarily 
microvascular origins, affecting small blood vessels (i.e., retinopathy/blindness, nephropathy/end-stage 
renal disease (ESRD), diabetic foot/lower-extremity amputation), and those with macrovascular origins, 
affecting large blood vessels (i.e., myocardial infarction (MI), chronic heart failure (CHF), angina 
pectoris, other ischemic heart disease (IHD), stroke). Information on yearly incidence rates of these 
complications in patients with type 2 diabetes are scarce in Germany, but generally, reported rates range 
from rather rare (e.g., <1% for amputations or blindness [32-34]) to moderately high (e.g. up to 6% for 
diabetic foot [35]). In addition, studies suggest that the actual lifetime prevalence rates are even higher 
(e.g., almost everyone with diabetes develops some degree of retinopathy) [36]. Taking also into account 
that multimorbidity is increasingly prevalent in the heterogeneous population of aging patients 
(especially those with diabetes), the term “high-need, high cost patients” has become widely used in 
recent years [37-39]. In the field of diabetes, associated complications have shown to make up the most 
common multimorbidity cluster [40]. Here, economic evaluations have found higher hospitalization 
costs due to macrovascular complications, and that costs gradually increase with the number of 
complications and higher levels of morbidity scores (i.e., adapted Diabetes Complications Severity 
Index) [41, 42]. However, a detailed examination of the longitudinal costs and the effect of specific 
interactions is missing. In addition, despite the growing scientific evidence, clinical guidelines still 
inconsistently consider aspects of multimorbidity in the development of recommendations for treatment 
and integrated disease control [43].  
What this thesis is able to add to the research of type 2 diabetes complications is a more differentiated 
and methodologically sophisticated analysis of the economic impact of various micro- and 
macrovascular complications and their co-occurrence. This includes, first, differentiating incident and 
prevalent complications and quantifying the longitudinal costs before and after the occurrence of new 
acute events or onset of chronic complications and, second, exploring different granularity levels of 
Introductory summary and motivation
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combining complications (e.g., from an aggregated count level to micro-/ macrovascular groups to 
specific complications) and quantifying the economic impact of diabetes-related multimorbidity and 
underlying interactions.  
 
1.3 Revealing potentials and pitfalls of claims data in the context of latest data trends 
“Imperfect data can still provide important answers” Raymond J. Gibbons [44] 
 
A crucial point in research is the realization that there is no database free of any bias. In short, this 
section aims to provide an essential understanding of the scientific value of health insurance claims data 
in the context of emerging paradigm shifts, and what this means for researching the costs of diabetes 
and its complications. Generally, in clinical research, randomized controlled trials (RCTs) are 
considered the gold standard in demonstrating the efficacy and safety of interventions [45]. However, 
long-term studies are rather rare, difficult and expensive to conduct and have its own limitations (e.g., 
limited generalizability and power to analyze rare outcomes). In addition, economic aspects are, if at 
all, only partly taken into account. Here, other data sources have become well-established, including 
data from various payer sources [46, 47]. In Germany, the vast majority of people (90%) are covered 
by over 100 statutory health insurance (SHI) funds that can vary in size, demographic characteristics 
and diabetes prevalence [48]. The content of these claims data is mostly regulated in the Fifth Book of 
the Social Law Code (§§ 294-303 SGB V). Although the data are primarily collected for reimbursement 
reasons, they contain many detailed information on (socio-)demographic characteristics, diagnoses and 
health services from outpatient and inpatient care, pharmaceuticals, rehabilitation and costs that are 
particularly useful for retrospective cohort studies [49, 50]. The two fast-growing research streams of 
real-world data and big data recognize health insurance claims data as an important contributing source 
[51]. Whereas “big data” is more focused on data management and analytic opportunities, “real-world 
data” is more related to a specific type of evidence generated from routine practice (e.g., on 
effectiveness, safety and economic impacts of interventions and care patterns). What both have in 
common is the potential to analyze larger volumes of data with high coverage and speed of availability, 
based on a wide variety of accepted statistical methods. In addition, studies based on real-world data 
can be more representative of the patient population and actual health care setting than in traditional 
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RCTs, are often cheaper to conduct and enable the examination of multiple interventions, outcomes and 
their interactions. However, SHI data in particular have also critical limitations that need to be 
considered throughout the study process, from data preparation/validation to interpretation of results. 
Some of the well-known limitations are limited or even lacking clinical and laboratory information (e.g., 
HbA1c, blood pressure, and lipids), the only quarterly documentation of outpatient diagnoses, time lags 
in the availability of claims data, and the maximum of four years of data storage for outpatient data 
(resulting in a reduced interpretability of the length of diabetes and its complications). Of at least similar 
importance are the hidden pitfalls of claims data resulting, for example, from selection effects within 
the SHI system or from physicians’ incomplete or implausible coding of diagnoses and other 
information that do not affect the payment. Regarding the first point, selection effects are one reason 
for differences in the prevalence rates of diabetes between various German SHI funds [48, 52, 53]. The 
second point, the coding practice, does not only affect the differentiation between diabetes types, but 
also the identification of chronic complications in the longitudinal setting and thus and the analysis of 
multimorbidity patterns and the accuracy of cost estimates.  
What this thesis is able to add to the research of real-world claims data is exploring key challenges and 
develop methodological strategies for claims data analyses of type 2 diabetes in Germany's largest 
nationwide SHI fund based on a large population and longitudinal setting. This especially includes 
applying and developing transparent validation routines not only in the data itself but also in the further 
processing and analysis (e.g., more accurate definition of type 2 versus type 1 and unspecified diabetes, 
and dealing with irregular patterns in the diagnosis of chronic complications).  
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1.4 Strengthening the use of accurate diabetes models to inform healthcare decisions 
“A model is a simplified representation of reality used to aid the understanding of key relationships and 
dynamics in the care process, and to evaluate the likely impact of changes before implementation.”  
Syed Mohiuddin [54] 
 
In short, this section aims to highlight the importance of accurately parametrized health economic 
diabetes models, to explain how simulation models work, and to identify important data and 
methodological requirements and possibilities for the economic parametrization of such a model. Two 
of the best-known non-commercial type 2 diabetes models are the United Kingdom Prospective 
Diabetes Study (UKPDS) model and the US model by the CDC (Center for Disease Control and 
Prevention) and RTI International (Research Triangle Institute) [55, 56]. Beyond the national context, 
key distinguishing features are primarily of methodological relevance, and include the model type 
(UKPDS microsimulation vs. CDC/RTI Markov cohort model) and scope (newly diagnosed diabetes in 
the UKPDS vs. additional screening for prediabetes/diabetes in the CDC/RTI model). Despite these 
differences, the core models are ought to produce same or similar results, given the fact that the 
CDC/RTI model is largely based on data from the 30-year UKPDS landmark trial. In particular, the 
UKPDS model (version 2.0) can be viewed as two parts. The epidemiological part contains the so-called 
“Risk Engine” that first calculates the lifetime probabilities of developing complications in individual 
patients based on their demographic characteristics (ethnicity, age, gender, duration of diabetes, weight, 
height), risk factor values (i.e., HbA1c, blood pressure, heart rate, HDL, LDL, hemoglobin, white blood 
cell count, smoking status, albuminuria status) and pre-existing events. The second part, the actual 
outcomes model, then assigns age group- and sex specific cost and quality of life values to different 
complication outcomes (no complications, fatal/nonfatal IHD, fatal/nonfatal MI, CHF, fatal/nonfatal 
stroke, amputation, blindness, end-stage renal disease, diabetic foot ulcer), both at the time of event and 
in subsequent years. As it is characteristic for a Markov model, the CDC/RTI model also computes the 
transition from early to late-stage complications (e.g., micro-/ macroalbuminuria leading to nephropathy 
and subsequently to ESRD, or retinopathy leading to blindness). Both models have been used, for 
example, to estimate the cost-effectiveness of intensified glycemic and hypertension control strategies, 
cholesterol-reducing medications, and lifestyle intervention programs [57-59]. In addition, the models 
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are regularly tested in validation challenges at the Mount Hood diabetes modeling conference that 
addresses the need for well-parametrized, robust and transparent models [60]. While there is currently 
no German type 2 diabetes model available, joint efforts of a research group at the German Diabetes 
Center in Düsseldorf and the Helmholtz Zentrum München are underway in this direction. This process 
includes three major steps: first, the examination of the adaptability of a comparable type 2 diabetes 
model to the German context, second, the collection of relevant data and parametrization of the 
(adapted) model and, third, the extensive validation and application of the model. Focusing on the 
second point, it has to be remembered that different sets of parameters require different data sources, 
e.g. efficacy data and transition probabilities of prevention and health care strategies are mostly gathered 
from clinical trials, whereas HRQoL values (utilities) are likely to be generated by cohort studies [61]. 
Regarding costs, diabetes models usually focus on direct medical costs. In particular, two major types 
of costs have to be distinguished here: intervention costs and complication costs [62]. While intervention 
costs can be directly derived from the trials itself, complication costs can be obtained either from 
separate literature sources (additive cost function) or from a single data-based regression of all 
predictors (additive or multiplicative cost function). For the regression approach, it is important to know 
that cost data usually follow a highly skewed distribution with a heavy tail and considerable number of 
zeros [63-65]. Traditionally, the additive cost function refers to the use of multiple sources, which can 
be biased due to heterogeneity reasons (e.g., different populations, time periods and settings) [62]. In 
diabetes modeling, the term is particularly used for the summative evaluation of the unit costs of 
complications (e.g., the costs of having both CHF and retinopathy would equal the costs of having CHF 
plus the costs of having retinopathy). The multiplicative approach is always a regression-based method 
that assumes a multiplicative linking of costs and may need transformation routines to obtain directly 
interpretable estimates. In the UKPDS model, Alva et al. used data of ~3500 patients to estimate an 
additive cost function based on a two-part model and bootstrap technique for inpatient costs (involving 
a logit and gamma generalized linear model (GLM) with identity link transformation), and a one-part 
gamma GLM for outpatient costs [66]. The CDC/RTI model reports both, an additive cost function 
based on multiple data sources, and a multiplicative cost function that mainly consists of baseline costs 
multiplied with the product of several multipliers associated with demographic variables, diabetes-
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related complications, and diabetes-related treatments [67]. In addition, the presence of disease 
interactions can indicate a more than additive relationship between complications (in other words, the 
effect of the co-occurring diseases is more than could be expected from adding their individual effects). 
The optimal choice of regression method should be carefully considered with regard to the study aims 
and may also depend on other factors, including convergence and computational performance, 
interpretability of results, quality of estimates (e.g., mean-squared error of the predictions vs. observed 
data), and ease of sensitivity analyses [68]. The availability of a large database provides a greater 
flexibility and variety in methods to assess diabetes costs, including the assumption of a normal 
distribution of costs with favorable properties for run-time efficiency, the quantification of probabilistic 
uncertainty, and direct interpretability of the results [64].  
What this thesis is able to add to the field of type 2 diabetes modeling is providing methodological input 
and empirical evidence on quantifying the costs of relevant complications, in order to improve the 
accuracy of model-based cost-effectiveness evaluations or even to build a German diabetes model. At 
first, this includes the development of a study design that is tailored to the economic parametrization of 
a type 2 diabetes model and its specific health states (e.g., incident/prevalent and fatal/nonfatal 
complications). Furthermore, this involves a more thorough examination of the additive or 
multiplicative linkage of diabetes costs and finally, a robust and detailed quantification of the total direct 
costs of complications (e.g., by using a larger dataset, considering time-dependent structures, and 
measuring interactions of specific complications with age, sex or other complications).   
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1.5 Guiding through this dissertation 
1.5.1 Goal of this dissertation and scope of published sub-studies 
This dissertation is based on a retrospective analysis of real-world patient-level data of the largest 
nationwide SHI fund, the Techniker Krankenkasse (10.2 million insured in mid-2018). The primary aim 
and long-term perspective of this dissertation was to contribute new empirical evidence and 
methodological approaches on the economic evaluation of various diabetes-related complications and, 
particularly, to inform the parametrization of type 2 diabetes models. The two sub-studies are based on 
quarterly data from 2012 (baseline year) and 3-year follow-up, on a total of 316,220 patients with type 
2 diabetes (63% male, mean age 65.6 years), who were selected based on the diagnostic codes E11 and 
E14, the prescription of oral antidiabetic medications, and participation in a disease management 
program for type 2 diabetes. 
The first study (published in Diabetes Care) describes the collection of the study population and focuses 
on providing robust empirical evidence on the total direct costs associated with the occurrence of 
diabetes-related complications. In detail, the study addresses the following questions:  
 How much do various incident complications of patients with type 2 diabetes cost the SHI system 
in the quarter of event/onset and thereafter? 
 How can type 2 diabetes and its complications be identified in claims data that are checked for 
consistency and plausibility?  
 Are there significant interactions between age, sex and the occurrence of complications on total 
costs? 
 How do the results compare with what is known from international diabetes models and other 
literature on the burden of diabetes? 
The second study (published in PharmacoEconomics) adds more in-depth empirical and especially 
methodological knowledge on the annual total costs associated with diabetes-related multimorbidity, 
with a strong focus on developing and exploring measures of different granularity.   
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In detail, the study addresses the following questions: 
 What is the economic impact of different strategies to assess the co-occurrence of multiple 
complications on total healthcare costs (ranging from an aggregated count level to the 
differentiation of micro-/ macrovascular groups to interactions between specific incident/prevalent 
complications)? 
 Which interaction patterns can be observed and visualized?  
 What validity issues arise from the cross-sectional and longitudinal analysis of claims data and how 
can they possibly be dealt with in standard routines?  
 How can the results be usefully implemented in diabetes simulation models? 
 
1.5.2 Individual contribution of the author 
The author (KK) of this cumulative thesis contributed substantially to all included articles. The 
conceptual ideas, study design and statistical analysis plan originated from or were substantially shaped 
by the author. KK selected, prepared and analyzed the data of the two studies independently at the 
Techniker Krankenkasse in Hamburg. She composed and finalized the underlying manuscripts and 
acted as corresponding author for the published articles. 
  
Introductory summary and motivation
24
 
103 
 
25 
1.6 References 
 
1. Riddle MC, Herman WH. The cost of diabetes care - an elephant in the room. Diabetes Care. 
2018 May;41(5):929-32. 
2. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. The 
Lancet Diabetes & Endocrinology. 2014 Jan;2(1):56-64. 
3. Oggioni C, Lara J, Wells JC, Soroka K, Siervo M. Shifts in population dietary patterns and 
physical inactivity as determinants of global trends in the prevalence of diabetes: an ecological analysis. 
Nutrition, Metabolism, and Cardiovascular Diseases. 2014 Oct;24(10):1105-11. 
4. Brinks R, Tamayo T, Kowall B, Rathmann W. Prevalence of type 2 diabetes in Germany in 
2040: Estimates from an epidemiological model. European Journal of Epidemiology. 2012 
Oct;27(10):791-7. 
5. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF 
Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes 
Research and Clinical Practice. 2018 Apr;138:271-81. 
6. Heidemann C, Du Y, Schubert I, Rathmann W, Scheidt-Nave C. [Prevalence and temporal trend 
of known diabetes mellitus: Results of the German Health Interview and Examination Survey for Adults 
(DEGS1)]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013 May;56(5-
6):668-77. 
7. Tamayo T, Brinks R, Hoyer A, Kuss OS, Rathmann W. The prevalence and incidence of 
diabetes in Germany. Deutsches Arzteblatt International. 2016 Mar 18;113(11):177-82. 
8. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the 
prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice. 2011 
Dec;94(3):311-21. 
9. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, 
prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 
countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 
2015 Aug;386(9995):743-800. 
10. Cummings M, Cunha-Vaz J. Treatment of neovascular age-related macular degeneration in 
patients with diabetes. Clinical Ophthalmology. 2008 Jun;2(2):369-75. 
11. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes 
Complications Severity Index in claims data. The American Journal of Managed Care. 2012 
Nov;18(11):721-6. 
12. Hunger M, Thorand B, Schunk M, Doring A, Menn P, Peters A, et al. Multimorbidity and 
health-related quality of life in the older population: results from the German KORA-age study. Health 
and Quality of Life Outcomes. 2011 Jul;9:53. 
13. Schunk M, Reitmeir P, Ruckert-Eheberg IM, Tamayo T, Schipf S, Meisinger C, et al. 
Longitudinal change in health-related quality of life in people with prevalent and incident type 2 
diabetes compared to diabetes-free controls. PLOS ONE. 2017 May;12(5):e0176895. 
14. Heidemann C, Scheidt-Nave C. Prevalence, incidence and mortality of diabetes mellitus in 
adults in Germany - A review in the framework of the diabetes surveillance. Journal of Health 
Monitoring. 2017;2(3):98–121. 
15. Fuchs S, Henschke C, Blumel M, Busse R. Disease management programs for type 2 diabetes 
in Germany: A systematic literature review evaluating effectiveness. Deutsches Arzteblatt International. 
2014 Jun;111(26):453-63. 
Introductory summary and motivation
25
 
103 
 
26 
16. Jacobs E, Hoyer A, Brinks R, Kuss O, Rathmann W. Burden of mortality attributable to 
diagnosed diabetes: A nationwide analysis based on claims data from 65 Million people in Germany. 
Diabetes Care. 2017 Dec;40(12):1703-9. 
17. IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes 
Atlas: Estimates for the year 2013. Diabetes Research and Clinical Practice. 2015 Sep;109(3):461-5. 
18. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes – prevalence and 
cost of illness in Germany: A study evaluating data from the statutory health insurance in Germany. 
Diabetic Medicine. 2006 Mar;23(3):299-305. 
19. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002 Jul;45(7):S5-
12. 
20. Köster I, Schubert I, Huppertz E. [Follow up of the CoDiM-Study: Cost of diabetes mellitus 
2000-2009]. Deutsche Medizinische Wochenschrift. 2012 May;137(19):1013-6. 
21. Köster I, Huppertz E, Hauner H, Schubert I. Direct costs of diabetes mellitus in Germany - 
CoDiM 2000-2007. Experimental and Clinical Endocrinology & Diabetes. 2011 Jun;119(6):377-85. 
22. Köster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the 
evidence from Germany - the CoDiM study. Diabetologia. 2006 Jul;49(7):1498-504. 
23. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T, et al. The 
global economic burden of diabetes in adults aged 20-79 years: A cost-of-illness study. The Lancet 
Diabetes & Endocrinology. 2017 Jun;5(6):423-30. 
24. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Barnighausen T, et al. 
Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care. 2018 
May;41(5):963-70. 
25. Ulrich S, Holle R, Wacker M, Stark R, Icks A, Thorand B, et al. Cost burden of type 2 diabetes 
in Germany: results from the population-based KORA studies. BMJ Open. 2016 Nov 21;6(11):e012527. 
26. von Ferber L, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess 
costs by age and type of treatment results of the German CoDiM Study. Experimental and Clinical 
Endocrinology & Diabetes. 2007 Feb;115(2):97-104. 
27. von Ferber L, Koster I, Hauner H. [Costs of the treatment of hyperglycemia in patients with 
diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM 
study]. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2006 May;101(5):384-93. 
28. Sieber C. [1+1+1 = Multimorbidity is more than the addition of monopathologies]. Deutsche 
Medizinische Wochenschrift. 2017 Aug;142(15):1089. 
29. Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel 
subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis 
of six variables. The Lancet Diabetes & Endocrinology. 2018 May;6(5):361-9. 
30. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes 
mellitus: Distinct or continuum? Indian Journal of Endocrinology and Metabolism. 2016 Jul-
Aug;20(4):546-51. 
31. Wilke T, Mueller S, Groth A, Fuchs A, Seitz L, Kienhofer J, et al. Treatment-dependent and 
treatment-independent risk factors associated with the risk of diabetes-related events: A retrospective 
analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 2015 
Feb;14:14. 
32. Kröger K, Berg C, Santosa F, Malyar N, Reinecke H. Lower limb amputation in Germany: An 
analysis of data from the German Federal Statistical Office between 2005 and 2014. Deutsches 
Ärzteblatt International. 2017;114(8):130-6. 
Introductory summary and motivation
26
 
103 
 
27 
33. Buckley CM, O'Farrell A, Canavan RJ, Lynch AD, De La Harpe DV, Bradley CP, et al. Trends 
in the incidence of lower extremity amputations in people with and without diabetes over a five-year 
period in the Republic of Ireland. PLOS ONE. 2012;7(7):e41492. 
34. Abholz HH, Egidi G, Zitterbart EU. Prävalenz von Folgeerkrankungen und Nutzen der 
Glukosesenkung bei Diabetes mellitus Typ 2. Deutscher Ärzte-Verlag | Zeitschrift für 
Allgemeinmedizin. 2015;91(5):220-6. 
35. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KVB), Arbeitsgemeinschaft 
der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Typ 2 Diabetes: Präventions- und 
Behandlungsstrategien für Fußkomplikationen. 2010; Available from: https://www.awmf.org/leitlinien 
(last accessed 6th Sept 2018). 
36. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of 
diabetes. BMJ. 2006;333(7566):475-80. 
37. Hartmann J, Jacobs S, Eberhard S, von Lengerke T, Amelung V. Analysing predictors for future 
high-cost patients using German SHI data to identify starting points for prevention. European Journal 
of Public Health. 2016;26(4):549-55. 
38. Blumenthal D, Chernof B, Fulmer T, Lumpkin J, Selberg J. Caring for high-need, high-cost 
patients - An urgent priority. The New England Journal of Medicine. 2016;375(10):909-11. 
39. Lin PJ, Pope E, Zhou FL. Comorbidity type and health care costs in type 2 diabetes: A 
retrospective claims database analysis. Diabetes Therapy. 2018 Aug 10 [Epub ahead of print]. 
40. Alonso-Moran E, Orueta JF, Esteban JI, Axpe JM, Gonzalez ML, Polanco NT, et al. 
Multimorbidity in people with type 2 diabetes in the Basque Country (Spain): Prevalence, comorbidity 
clusters and comparison with other chronic patients. European Journal of Internal Medicine. 2015 
Apr;26(3):197-202. 
41. Nuno-Solinis R, Alonso-Moran E, Arteagoitia Axpe JM, Ezkurra Loiola P, Orueta JF, 
Gaztambide S. Healthcare costs of people with type 2 diabetes mellitus in the Basque Country (Spain). 
Endocrinología y Nutrición. 2016 Dec;63(10):543-50. 
42. Chen HL, Hsu WW, Hsiao FY. Changes in prevalence of diabetic complications and associated 
healthcare costs during a 10-year follow-up period among a nationwide diabetic cohort. Journal of 
Diabetes and its Complications. 2015 May-Jun;29(4):523-8. 
43. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges 
of applying UK clinical guidelines to people with multimorbidity. Age and Ageing. 2013 Jan;42(1):62-
9. 
44. Gibbons RJ. Imperfect data can still provide important answers. JACC: Cardiovasc Imaging. 
2018 June 8 [Epub ahead of print]. 
45. Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient? Health Affairs. 2005 Jan-
Feb;24(1):93-101. 
46. Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. 
Pharmacotherapy. 2009 Feb;29(2):138-53. 
47. Schubert I, Köster I, Küpper-Nybelen J, Ihle P. Versorgungsforschung mit GKV-Routinedaten. 
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2008 October 01;51(10):1095-
105. 
48. Hoffmann F, Icks A. Diabetes prevalence based on health insurance claims: large differences 
between companies. Diabetic Medicine. 2011 Aug;28(8):919-23. 
49. Gansen FM. Health economic evaluations based on routine data in Germany: A systematic 
review. BMC Health Services Research. 2018 Apr;18(1):268. 
Introductory summary and motivation
27
 
103 
 
28 
50. Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data 
analyses in Germany - A systematic review. Health Policy. 2016 Feb;120(2):213-26. 
51. Einav L, Levin J. Economics in the age of big data. Science. 2014 Nov 7;346(6210):1243089. 
52. Hoffmann F, Icks A. [Structural differences between health insurance funds and their impact 
on health services research: Results from the Bertelsmann Health-Care Monitor]. Gesundheitswesen. 
2012 May;74(5):291-7. 
53. Altenhofen L, Hagen B, Kretschmann J, Groos S, Graf von Stillfried D. Collective was not 
representative. Deutsches Ärzteblatt International. 2011;108(42):722. 
54. Mohiuddin S, Busby J, Savovic J, Richards A, Northstone K, Hollingworth W, et al. Patient 
flow within UK emergency departments: A systematic review of the use of computer simulation 
modelling methods. BMJ Open. 2017 May;7(5):e015007. 
55. Govan L, Wu O, Lindsay R, Briggs A. How do diabetes models measure up? A review of 
diabetes economic models and ADA guidelines. Journal of Health Economics and Outcomes Research. 
2015;3(2):132-52. 
56. Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, et al. A 
review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. 
PharmacoEconomics. 2010;28(4):255-77. 
57. Laxy M, Wilson ECF, Boothby CE, Griffin SJ. Incremental costs and cost-effectiveness of 
intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK 
trial: An update with empirical trial–based cost data. Value in Health. 2017. 
58. Zhuo X, Zhang P, Gregg EW, Barker L, Hoerger TJ, Tony P-C, et al. A nationwide community-
based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. 
Health Affairs. 2012 Jan;31(1):50-60. 
59. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, 
intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002 
May;287(19):2542-51. 
60. Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, et al. Computer modeling of diabetes 
and its transparency: A report on the Eighth Mount Hood Challenge. Value in Health. 2018. 
61. Paisley S. Classification of evidence in decision-analytic models of cost-effectiveness: a content 
analysis of published reports. International Journal of Technology Assessment in Health Care. 2010 
Oct;26(4):458-62. 
62. Hoerger TJ. Using costs in cost-effectiveness models for chronic diseases: lessons from 
diabetes. Medical Care. 2009 Jul;47(7 Suppl 1):S21-7. 
63. Barber J, Thompson S. Multiple regression of cost data: Use of generalised linear models. 
Journal of Health Services Research & Policy. 2004 Oct;9(4):197-204. 
64. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing 
healthcare resources and costs. Health Economics. 2011 Aug;20(8):897-916. 
65. Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for 
analyzing costs and their determinants in health care: an introductory review. International Journal for 
Quality in Health Care. 2011 Jun;23(3):331-41. 
66. Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related 
complications on healthcare costs: New results from the UKPDS (UKPDS 84). Diabetic Medicine. 2015 
Apr;32(4):459-66. 
Introductory summary and motivation
28
 
103 
 
29 
67. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, et al. The direct medical cost 
of type 2 diabetes. Diabetes Care. 2003 Aug;26(8):2300-4. 
68. Pagano E, Petrelli A, Picariello R, Merletti F, Gnavi R, Bruno G. Is the choice of the statistical 
model relevant in the cost estimation of patients with chronic diseases? An empirical approach by the 
Piedmont Diabetes Registry. BMC Health Services Research. 2015 Dec 30;15:582. 
  
Introductory summary and motivation
29
 
103 
 
30 
2 Article 1: “Health care costs associated with incident complications in patients with 
type 2 diabetes in Germany” 
 
 
 
Published in: 
Kähm K., Laxy M., Schneider U., Rogowski W.H., Lhachimi S.K., Holle R.: Health care costs 
associated with incident complications in type 2 diabetes in Germany. Diabetes Care 2018; 41(5): 971-
978. 
 
  
Article 1
30
 
103 
 
Health Care Costs AssociatedWith
Incident Complications in Patients
With Type 2 Diabetes in Germany
Diabetes Care 2018;41:971–978 | https://doi.org/10.2337/dc17-1763
OBJECTIVE
The aim of this study is to provide reliable regression-based estimates of costs asso-
ciated with different type 2 diabetes complications.
RESEARCH DESIGN AND METHODS
We used nationwide statutory health insurance (SHI) data from 316,220 patients
with type 2 diabetes. Costs for inpatient and outpatient care, pharmaceuticals,
rehabilitation, and nonmedical aids and appliances were assessed in the years
2013–2015. Quarterly observations are available for each year. We estimated costs
(in 2015 euro) for complications using a generalized estimating equations model
with a normal distribution adjusted for age, sex, occurrence of different complica-
tions, and history of complications at baseline, 2012. Two- and threefold interactions
were included in an extended model.
RESULTS
The base case model estimated total costs in the quarter of event for the example
of a 60- to 69-year-old man as follows: diabetic foot V1,293, amputation V14,284,
retinopathy V671, blindness V2,933, nephropathyV3,353, end-stage renal disease
(ESRD) V22,691, nonfatal stroke V9,769, fatal stroke V11,176, nonfatal myocardial
infarction (MI)/cardiac arrest (CA) V8,035, fatal MI/CA V8,700, nonfatal ischemic
heart disease (IHD) V6,548, fatal IHD V20,942, chronic heart failure V3,912, and
angina pectoris V2,695. In the subsequent quarters, costs ranged from V681 for
retinopathy to V6,130 for ESRD.
CONCLUSIONS
Type 2 diabetes complications have a signiﬁcant impact on total health care costs in
the SHI system, not only in thequarter of eventbut also in subsequent years.Menand
women from different age-groups differ in their costs for complications. Our com-
prehensive estimates may support the parametrization of diabetes models and help
clinicians and policy makers to quantify the economic burden of diabetes complica-
tions in the context of new prevention and treatment programs.
In Germany, the prevalence of type 2 diabetes was estimated at;7% in 2011, which is
slightly above the global average (1,2). Type 2 is the most common form of diabetes,
accounting for .90% of all diabetes cases, and is largely the result of lifestyle and
behavioral risk factors. The shift in risk factors aswell as demographics is contributing to
the increasing prevalence worldwide, especially among younger age-groups (3). This
increased prevalence adds to the growing social and economic burden of diabetes,
which is further driven by the occurrence ofmultiple heterogeneous complications (4).
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As new diabetes treatments and preven-
tion programs are introduced to address
these issues, economic evaluations are
becoming more important. Tools such as
systematic disease models can assist de-
cision makers in assessing the impact on
clinical outcomes and economic perfor-
mance. The twowidely usednoncommer-
cial type 2 diabetes models that have a
substantive overlap include the Centers
for Disease Control and Prevention/RTI
International (CDC/RTI) model and the
UK Prospective Diabetes Study (UKPDS)
Outcomes Model (5,6). Both models fol-
low patients over a lifetime horizon and
simulate the development of various com-
plications, includingmicrovascular com-
plications (nephropathy, diabetic foot,
and retinopathy) aswell asmacrovascular
complications. Thesemodels have, for ex-
ample, been used to estimate the cost-
effectiveness of an intensive glycemic
control regimen, a cholesterol-reducing
regimen, or other intervention programs
(7,8). So far, there is no literature on a
comparable German model for type 2 di-
abetes. Although the risk engines are
probably transferable to Caucasian popu-
lations, costs mostly remain country spe-
ciﬁc. Reliable estimates are therefore
needed for the use of diabetes models
in the German context. To date, there
are only a few related studies focusing on
the health care costs of diabetes compli-
cations in Germany. However, none of
these studies fulﬁlls all the requirements
necessary for a complete implementation
and parametrization of such a diabetes
model. Speciﬁcally, they do not distin-
guish between type1 and type2diabetes,
do not account for the temporal distribu-
tion of costs, exclude deaths, use a restric-
tive sample (e.g., from the stateHesse), or
focus on just one single complication
(9–11). With regard to the data source
to be used, health claims data are the
most suitable source because of the large
sample size, wide coverage, and detailed
cost data covering several years.
This study therefore uses nationwide
health insurance data from Germany to
comprehensively estimate the short- and
medium-term costs of typical type 2 di-
abetes–related complications within a re-
gression approach. These estimates can
be used for the parametrization of diabe-
tes models such as UKPDS and CDC/RTI
and are helpful for clinicians and decision
makers in quantifying the economic bur-
den of diabetes complications.
RESEARCH DESIGN AND METHODS
Research Setting
In Germany, every citizen is required to
have health insurance (either private or
statutory). Currently, there are.100 stat-
utory health insurance (SHI) funds, which
are mainly historically evolved and cover
;90% of the population.
Each person is assigned a unique pseu-
donymous identiﬁcation number, which
allows every insurance fund to capture in-
formation from the same person until
death, end of insurance, or even with in-
terruptions in the insurance history. In this
retrospective cohort study, we use claims
data from the Techniker Krankenkasse
(TK), which is the largest nationwide SHI
provider in Germany, covering;9.8 million
insured people in the ﬁrst half of 2017
throughout Germany.
Health claims data (especially outpa-
tient service data) are by German social
laws only available for the last 4 years.
The data extraction was performed at
the end of 2016; therefore, the baseline
year was 2012. The development of com-
plications and costs was then assessed
during the follow-up period in 2013–
2015. All analyses were performed at
the WINEG institute (Scientiﬁc Institute
of TK for Beneﬁt and Efﬁciency in Health
Care), who approved the intended use
of the data. According to ofﬁcial guide-
lines, the consultation of an ethics com-
mittee is not required because of the
retrospective design of the study and the
on-site evaluation of data at the WINEG
institute (12).
Selection of Study Population:
Inclusion and Exclusion Criteria
The deﬁnition of type 2 diabetes follows a
recent publication on the incidence and
prevalence of diabetes in Germany (13).
In this study, Tamayo et al. (13) propose a
way of distinguishing between different
groups of patients with diabetes based on
outpatient and inpatient ICD-10 diagnoses
E10–E14, namely type 1, type 2, unclear
type 1 or 2, unspeciﬁed, or other diabe-
tes. For our analysis, we concentrated
on the group of patients with clear type 2
diabetes but also considered potential
type 2 diabetes in the group with an un-
clear or unspeciﬁed diabetes diagnosis.
Therefore, we linked the inclusion criteria
to the prescription of oral antidiabetes
medications and participation in a disease-
management program (DMP) for type 2
diabetes. Regarding the ﬁrst point,
for example, the most commonly pre-
scribed antidiabetes agent metformin is
not licensed for individuals without dia-
betes in Germany. On the second point, it
should be noted that .60% of the pop-
ulation with diabetes participates in a
DMP for type 2 diabetes (14,15). A more
detailed technical deﬁnition can be found
in Supplementary Table 1. Before begin-
ning the data selection, we also compared
the diabetes prevalence calculated based
on the TK population (standardized to the
German population in 2011) with other lit-
erature. Exclusion criteria included age,18
years, certain diseases such as gestational
diabetes mellitus (ICD-10 O24), pancreo-
privic diabetes (E13), and pancreatic can-
cer, and participation in a DMP for type 1
diabetes. Furthermore, we excluded pa-
tientswith an incomplete insurance history
until death in the follow-up period and
patients with unknown residence or resi-
dence abroad at baseline. The ﬂowchart
for the cohort selection is shown in Fig. 1.
Identiﬁcation of Diabetes-Associated
Complications
This study investigates macrovascular
complications, including angina pectoris,
chronic heart failure (CHF), myocardial in-
farction (MI)/cardiac arrest (CA), stroke,
and other ischemic heart diseases (IHDs),
as well asmicrovascular complications, in-
cluding retinopathy, blindness, diabetic
foot, lower-extremity amputation (LEA),
nephropathy, and end-stage renal dis-
ease (ESRD). These are the complications
in the UKPDS and CDC/RTI diabetes
model, which were identiﬁed based on
corresponding medical codes that were
collected from the literature and publicly
accessible databases (see Supplementary
Tables 2 and 3 for full details of the oper-
ationalization of complications, risk fac-
tors, and medications) (16–28). Inclusion
criteria for complications required that
at least oneoutpatient or oneprimary or
secondary inpatient ICD diagnosis was
documented in the follow-up period.
Complications with only one suspected
diagnosis in one quarter were not taken
into account. For some complications
(i.e., LEA or dialysis-dependent renal in-
sufﬁciency), inpatient operation/procedure
codes and outpatient service codes were
also used. Moreover, acute macrovascu-
lar complications (MI/CA, stroke, and
IHD) were deﬁned as nonfatal or fatal
events that were limited to hospitalizations
with primary diagnosis. Fatal macrovascular
972 Costs of Type 2 Diabetes in Germany Diabetes Care Volume 41, May 2018
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complications additionally required death
as the discharge reason. The quarter of
an incident complication was detected
in the follow-up period by requiring a
washout period of 1 year (that is the
baseline year 2012) free of diagnoses of
the speciﬁc complication. If a complica-
tion was present at baseline, patients
were assigned as having a history of the
complication.
Resources and Costs
By applying an SHI perspective, health
care costs include costs for outpatient
and inpatient services, medication, reha-
bilitation, and the provision of aids and
appliances. Therefore, copayments to
medical services covered by SHI are in-
cluded in the data set, whereas patients’
out-of-pocket payments for other serv-
ices are not. All costs are expressed in
2015 euros using ofﬁcial inﬂation data
from the Federal Statistical Ofﬁce (29).
Outpatient diagnoses are only available
on a quarter level. For inpatient data,
the admission and discharge dates are
available. In line with an SHI perspective,
we used the discharge date to determine
the corresponding quarter.
Data Preprocessing and Statistical
Analysis
Before the actual statistical analysis, data
were subjected to quality and plausibility
checks as requested by common guide-
lines for secondary data analysis (12).
This included, for example, checking for
negative or zero total hospital payments,
implausible lengths of stay in hospital, or
charged costs after death (see Supple-
mentary Table 4). Additionally, cost data
were plotted in a boxplot and histogram
to identify possible outliers. We prepared
the data in the form of 12 observation
periods of 3 months per patient, repre-
senting the number of calendar quarters
in the 3-year follow-up period. We al-
lowed for deviations of the time of onset
of the complication by consecutively
numbering quarters without complica-
tion with zero, the quarter of event with
1, and the following quarters with 2 to up
to 12. In accordance with the require-
ments of the implementation of costs in
diabetes models, we estimated the im-
pact of complications in at least two
time periods: within the quarter in which
the complication occurs and in subse-
quent quarters (i.e., ,1 year after the
onset of complication and .1 year after
the onset of complication). Similar to Alva
et al. (22), we assume that the later time
periods are likely to reﬂect the ongoing
impact of complications, including subse-
quent events of the same type. Patients
who already experienced this complica-
tion at baseline are extracted in separate
dummy variables, which stay the same
during the follow-up period. All patients
were followed up until death or end of
2015. A generalized estimating equations
(GEE) model was used to account for the
nonindependence of observations within
each subject during the period of the
study (see Supplementary Statistical
Appendix for the detailed model nota-
tion). In line with literature recommenda-
tions, we can assume a near normality of
the sample means, as the sample size is
sufﬁciently large and the proportion of
zero costs relatively small (,2%) (30).
Furthermore, the GEE model with a nor-
mal distribution showed better model ﬁt
based on the mean square error and re-
sidual plot compared with a g-based GEE
model where V1 was assigned for pa-
tients with zero costs. While the normal
distribution also has favorable properties
Figure 1—Selection algorithm for patientswith type 2 diabetes (baseline year 2012). *At time of data selection (December 2016). Therefore, patientswith
temporary stay abroad are still included in the population. T1D, type 1 diabetes.
care.diabetesjournals.org Ka¨hm and Associates 973
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for run-time efﬁciency, the quantiﬁcation
of probabilistic uncertainty, and the inter-
pretability of results, other data transfor-
mation methods, such as the logarithmic
transformation, have several drawbacks
on their own (31). To address challenges
associated with extreme outliers, costs
were winsorized at 99.9% (by sex) in a sen-
sitivity analysis. Winsorization is a way to
minimize the inﬂuence of outliers in the
data by replacing extreme values based
on percentiles. All analyses were per-
formed using SAS Enterprise Guide ver-
sion 7.1 with SAS version 9.4 (SAS Institute
Inc., Cary, NC).
RESULTS
Sample Characteristics
Table 1 describes the baseline sociodemo-
graphic and clinical characteristics of the
study sample, which consisted of 316,220
patients. Approximately 61% of the popu-
lation was found to participate in a DMP
for type 2 diabetes in 2012. Hypertension
and obesity were frequently present in
;81% and 30%, respectively. Obesity
and depression were thereby more fre-
quent in women (34% vs. 28% and 26%
vs. 14%), whereas alcohol and tobacco
abuse and malignant cancer were more
frequent in men (10% vs. 7% and 16% vs.
13%). Men also exhibited a slightly higher
adapted Diabetes Complication Severity
Index (aDCSI) score of 1.9 vs. 1.5 (see
Supplementary Tables 5 and 6 for further
details on the calculationof theaDCSI score
and distribution in the population) (25).
Diabetes Prevalence
In the TK population, the standardized
prevalence of clear type 2 diabetes cases
(ICD E11) was calculated at 5.6% in 2012
(6.15% for men and 5.10% for women).
When takingall diabetes forms intoaccount
(including unclear or unspeciﬁed type 2
diabetes but also type 1 and other types
of diabetes), an overall prevalence of 8.5%
and 7.0% was calculated for men and
women, respectively.
Descriptive Analysis
In our population, complications occurred
withthefollowingfrequencies:nephropathy
(17.7% observed new cases), diabetic foot
(15.5%), CHF (13.4%), retinopathy (11.3%),
anginapectoris (5.5%), stroke (2.5%),MI/CA
(2.0%), other IHD (2.0%), ESRD (1.2%),
amputation (0.6%), and blindness (0.6%).
On the cost side, total raw mean costs
increased fromV4,688 in 2013 by;5.6%
to V4,949 in 2015 (see Supplementary
Fig. 1A andB).Mostof the costs are related
to inpatient care (42%), pharmaceuticals
(27%), and physician care (20%). In age-
groups ,60 years, costs were higher in
women, whereas costs were higher in
men in higher age-groups. Figure 2 shows
the development of costs before, during,
and after the occurrence or onset of cer-
tain complications (information on the
number of patients that were included
in the calculations as well as the cost fac-
tor relative to the absence of complica-
tions can be found in Supplementary Fig.
2). Costs in the quarter of event were the
highest for LEA, ESRD, and all three acute
events (MI/CA, stroke, and other IHD),
ranging fromV9,309 toV30,739 for non-
fatal and fatal IHD, respectively. The dis-
tribution of costs indicates no or only a
slight peak for chronically evolving com-
plications such as retinopathy, nephropa-
thy, or foot complications at the quarter of
ﬁrst diagnosis. The costs here are growing
slowly or remain stagnant. This is in con-
trast to acute or very severe complications
such as LEA, ESRD, and acutemacrovascu-
lar events, where a clear high peak can be
identiﬁed. There is also a difference be-
tween LEA and acutemacrovascular com-
plications, showing that the decline in
costs is relatively slower for acute macro-
vascular complications in the subsequent
periods.
Regression Analysis
Table 2 shows the estimated coefﬁcients
obtained from the GEE model. Because
the estimates are directly interpreted as
costs, the intercept of V780 represents
ﬁxed costs for a female patient aged
70–79 years without any complications
for a 3-month period, which corresponds
to about V3,120 for a whole year. The
same patient with a diabetic foot diagno-
sis would have additional costs of around
V640 for the quarter of diagnosis and
around V370 of additional costs in the
following quarters. Owing to the large
sample size, conﬁdence intervals will be
small. Supplementary Tables 7 and 8 re-
port estimates and predictions of costs
from the regression, including interaction
effects between age, sex, and complica-
tions. Total costs were calculated sepa-
rately for men, women, and age-groups
tomeet the basic requirements formodel
parametrization. In addition, results are
also presented on an annualized basis.
The annualized costs per complication
(in 2015 euros) for the example of a 60-
to 69-year-old man ranged from V2,539
for retinopathy to V34,547 for ESRD in
the year of event, and from V2,469 to
V24,662 for retinopathy and ESRD in
the following years, respectively. Costs
Table 1—Baseline characteristics in 2012
Overall
(n = 316,220)
Female
(n = 116,010)
Male
(n = 200,210)
Participation in the DMP for type 2 diabetes (%)* 61.2 61.0 61.3
Sex (%) 36.7 63.3
Age, years, mean (min, max) 65.9 (18, 106) 66.3 (18, 101) 65.6 (18, 106)
Age-group, years, %
,50 8.6 9.3 8.2
50–59 19.4 18.2 20.1
60–69 29.6 28.0 30.5
70–79 32.4 32.1 32.6
.80 10.0 12.4 8.5
Type of antidiabetes treatment, %
None 37.9 42.3 35.3
Only oral 47.4 44.6 48.9
Oral + insulin 9.2 8.1 9.9
Only insulin 5.5 5.0 5.9
aDCSI score, mean (min, max) 1.747 (0, 12) 1.545 (0, 12) 1.864 (0, 12)
Risk factors (ICD codes), %
Hypertension (I10–I15) 80.5 80.0 80.7
Alcohol/tobacco (F10, F17) 9.0 6.6 10.4
Depression (F32–F34) 18.4 26.3 13.8
Obesity (E66) 30.1 34.2 27.7
Sleeping disorder (G47, F51) 12.9 12.0 13.4
Malignant cancer (C00–C97) 14.7 13.1 15.7
max, maximum; min, minimum. *Participation for at least 1 day.
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of other fatal IHD were also estimated to
be very high, but the SE is the highest
because of the small number of patients.
It is also noticeable that men have higher
costs in most age-groups in the event
quarter for macrovascular complications,
severe renal complications, and LEA. The
differences range from;5% higher costs
for LEA to .80% for fatal MI and more
than double for fatal IHD. For acute mac-
rovascular complications, sex differences
are higher for fatal than for nonfatal
events. Women, in contrast, have higher
costs in the ﬁrst quarter of microvascular
complications such as diabetic foot, reti-
nopathy, and blindness, and for macro-
vascular complications only in speciﬁc
age-groups. The differences here range
from 20% to 30% higher costs for blind-
ness to .50% for retinopathy in the
younger age-groups. For retinopathy
and diabetic foot, sex differences in costs
decrease with higher age-group or even
reverse, as for diabetic foot complica-
tions. In addition,women also havehigher
costs in the follow-up quarters for thema-
jority of complications except ESRD. This
especially applies to the younger age-
groups, whereas the effect often declines
in older age-groups. Additional cross-
validationwas performed by relatively com-
paringour resultswith theUKPDSOutcomes
Model (version 2) based on the example
of a 70- to 79-year-old patient (see Supple-
mentary Table 9).
Sensitivity Analysis
In the sensitivity analysis using winsoriza-
tion, estimateshavegenerally not changed
greatly (results are available on request).
The largest changes of 11%–42% reduced
costs were mainly related to those com-
plications that are known to be rather
rare and expensive (e.g., ESRD, amputa-
tion, and fatal macrovascular events).
CONCLUSIONS
There is, to our knowledge, no comparable
study thatprovides anoverall pictureof the
impact of many diabetes-related complica-
tions on health care costs in Germany. This
study is, therefore, the ﬁrst providing suf-
ﬁciently detailed information on the real-
life costs of patientswith type2diabetes for
a variety of acute or chronic microvascular
and macrovascular complications based on
nationwide German claims data for 2012–
2015. The results not only show that costs
are increased in the quarter in which the
event/disease occurs but also show that
they continue tobeelevated in subsequent
years. Second, it becomes apparent that
women and men in different age-groups
differ in the costs of their complications.
Comparison and Cross-Validation
With Other Studies
In 2012, the standardized prevalence of
clear type 2 diabetes cases (ICD E11) was
lower compared with the estimate of
Tamayo et al. (13) for 2010 (5.6% vs.
7.1%). This is in line with a comparison
study between different health insurance
funds in Germany that resulted in a prev-
alence of 5.8% for the TK compared with
6.9% overall (32). However, given knowl-
edge about the large numbers ofmisdiag-
nosed diabetes cases, the total diabetes
prevalence of 8.5% and 7.0% for men and
women is overall comparable with other
literature (2,33). This also reﬂects the im-
portance of choosing an appropriate se-
lection strategy forpotential type2diabetes
cases. The proportion of patients who had
no antidiabetes treatment at baseline was
relatively high (37.9%) compared with the
literature (20% forGermany) (34). However,
the widely published Costs of Diabetes
Mellitus (CoDiM) study also reported a
higher percentage of 29.4%, which is com-
parable toourﬁndings forDMPparticipants
(28.6%) (35). Thereason for thishighervalue
cannot be fully determined; it could be
because of a healthier patient sample, im-
proveddiseasemonitoring, or false-positive
or less severe/prediabetic cases.
Total rawmean costs ofV4,688 (2013)
are in the same range as reported in other
studies, including the CoDiM study and
others (V5,993 and V4,377 in 2010, re-
spectively) (21,36).Wealso cross-validated
our results by comparing calculated cost
factors for each complication (relative
to no complications) with the UKPDS
Outcomes Model based on the example
of a 70- to 79-year-old patient. Generally,
Figure 2—Distribution of raw total costs before and after the occurrence of acute events or onset of chronic complications in quarterly intervals. Costs
were not standardized and refer to the patients who were alive or died in the same quarter during the follow-up period (see Supplementary Fig. 2 for
further details). Time zero is themean over patients and quarterswithout complication; “1” is the quarterwhere the complication occurs/starts.A: Lower-
extremity complications.B: Eye complications.C: Chronic heart complications.D: Renal complications. E: Acute fatalmacrovascular complications. F: Acute
nonfatal macrovascular complications.
care.diabetesjournals.org Ka¨hm and Associates 975
Article 1
35
 
103 
 
a reasonable level of congruence was ob-
served, with greater deviations for IHD
and diabetic foot. However, greater uncer-
tainty has to be considered in our regres-
sionmodel regarding IHD. In thepublication
by Alva et al. (22) on the updated cost
estimations in the UKPDS model, female
patients in most age-groups and com-
plications were assumed to have higher
costs (except for ESRD and foot ulcer,
where the same costs are assumed in the
model). When considering interactions be-
tween age, sex, and complications, it was
noticeable that our study reveals more dif-
ferences between men and women. Ac-
cordingly, in the event quarter, men had
higher costs in most age-groups for ESRD,
LEA, and macrovascular complications,
whereas women had higher costs for
other microvascular complications. Also,
women had higher costs in the follow-up
quarters for the majority of complications
except ESRD. However, because of a
lowernumberof cases in someage-groups,
interaction estimates do not always show
signiﬁcant effects and should be inter-
preted with caution. Important reasons
for these sex differences in health care
costs could be potentially different causes
of the disease (e.g., hemorrhagic versus
ischemic stroke and role of psychological
factors in women), different severity, or
differences in disease management (e.g.,
less invasive treatments in women with
MI) (37). From a methodological point
of view, it is also important to consider
the age distribution in the different age-
groups.Mean age is the same in themiddle
age-groups, whereas women are 2 years
younger than men in the age-group ,50
years (44 vs. 42 years) and 1 year older
than en in the group .80 years (83 vs.
84 years).
Strengths and Weaknesses of This
Study
This study uses the method of regression
analysis to provide reliable estimates of
Table 2—Effects of acute events and chronic type 2 diabetes complications on total costs per quarter in GEE normal regression
Variable Coefﬁcient estimate (SE)
Constant 779.7*** (7.9)
Sex: male (Ref = female) 257.1*** (6.3)
Age-group (Ref = 70–79 years), years†
,50 2128.3*** (12.6)
50–59 2116.3*** (9.2)
60–69 269.2*** (8.4)
.80 2195.1*** (12.0)
Coefﬁcient estimate (SE)
Event/condition (Ref = no) Quarter/time of event ,1 year after the event‡ .1 year after the event‡
Diabetic foot 639.3*** (30.8) 369.2*** (17.0) 356.0*** (23.0)
Amputation 13,630.3*** (482.0) 2,665.9*** (168.8) 1,967.9*** (319.3)
Retinopathy 17.5 (16.0) 27.2 (14.2) 39.1* (18.0)
Blindness 2,279.9 (177.3) 487.1 (67.6) 316.2 (80.3)
Nephropathy 2,699.3*** (47.2) 702.0*** (19.3) 432.7*** (21.4)
ESRD 22,037.6*** (700.4) 5,476.4*** (195.5) 4,605.9*** (293.0)
Fatal MI 8,046.2*** (950.8) NA NA
Nonfatal MI 7,381.7*** (152.6) 820.8*** (73.5) 220.6** (71.3)
Fatal IHD 20,288.4*** (5,251.3) NA NA
Nonfatal IHD 5,894.9*** (141.4) 523.3*** (69.9) 171.2*** (52.3)
CHF 3,258.5*** (55.3) 868.7*** (24.0) 549.7*** (24.4)
Fatal stroke 10,522.9*** (903.5) NA NA
Nonfatal stroke 9,115.6*** (155.5) 2,168.8*** (88.7) 642.6*** (54.8)
Angina pectoris 2,041.9*** (50.4) 242.2*** (27.6) 106.3** (35.7)
Death for other reasons 5,589.0*** (124.2) NA NA
History in 2012 (Ref = no) Coefﬁcient estimate (SE)
Diabetic foot 372.5*** (13.9)
Amputation 2,017.4*** (171.1)
Retinopathy 63.2*** (9.3)
Blindness 196.2*** (47.5)
Nephropathy 408.8*** (11.1)
ESRD 6,902.3*** (164.3)
Nonfatal MI 52.1 (46.3)
Nonfatal IHD 566.1*** (25.4)
CHF 532.6*** (12.8)
Angina pectoris 211.6 (19.4)
Nonfatal stroke 635.2*** (46.5)
Number of observations 3,663,240
Number of patients 316,220
NA, not applicable; Ref, reference. *P ,0.05. **P,0.01. ***P,0.001. †The interactions between age and sex as well as threefold interactions with
complications are omitted here for visibility reasons. The extendedmodel aswell as estimated costs by age-group and sex can be found in Supplementary
Tables 7 and 8. ‡“Event” refers to the quarter when the diabetes complication ﬁrst occurred/started.
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costs associated with different type 2 di-
abetes complications, adjusted for age,
sex, a large set of preexisting complications
at baseline, and other two- or three-factor
interactions. It was considered to not con-
trol for other chronic comorbidities for sev-
eral reasons,whichmight have aneffect on
the results. First, to avoid overadjustment,
it would be a crucial point to identify func-
tionally fully independent conditions that
are unrelated to the complications of in-
terest. This is especially difﬁcult, since di-
abetes and its complications are affecting
the whole body system. Second, we have
good evidence that age is the main predic-
tor of comorbidity (38). Third, we explored
the potential bias using the example of
obesity, showing that most of the esti-
mates do not differ much at all or at least
not signiﬁcantly.
The analysis itself was based on health
insurance data that can be regarded as
the best available data source for health
care costs in Germany; however, inherent
advantages and disadvantages must be
considered. First, the representativeness
of the data has to be assessed. Despite
the high population coverage and the na-
tionwide scope of the TK database, a
small selection bias cannot be excluded
for any of the insurance providers (32).
In this case, the age distribution of the
TK population is slightly skewed toward
younger people (compared with the gen-
eral population); however, the mean age
of patients with diabetes in our popula-
tion is comparable with other studies
(35).
Second, there are only limited clinical
data covered by health claims data. This
means that the identiﬁcation of complica-
tions is relying on accurate clinical diag-
noses and clinical history information at
baseline and that the length of diabetes
is unknown. However, regarding the lat-
ter point, most diabetes models by their
nature require mean cost values as input
parameters for practical modeling rea-
sons. What we also have is relatively ro-
bust information on the severity of
diabetes at baseline (e.g., from treatment
type, aDCSI score, and presence of cer-
tain risk factors). In addition, we use the
information on the history of complica-
tions at baseline as an indicator to cope
with not having prospective clinical data
from newly diagnosed patients with dia-
betes (as in the UKPDS). It is important
that most of these clinical trials are very
expensive to conduct and are often still
too short to measure the complication
costs for many chronic diseases (39). When
focusing on cost data, a major strength
of this study can therefore be seen in
the real-world setting in which the costs
are incurred by a large population expe-
riencing natural heterogeneity. The sam-
ple size of .300,000 patients with type
2 diabetes also guaranteed the statistical
power to investigate rather rare compli-
cations (i.e., ESRD, blindness, and ampu-
tation). In addition, claims data are not
subjected to recall bias, which can be an
issue in clinical trials. Finally, another
strength of this study is the reference to
international diabetes models, which al-
lows better cross-validation. A lack of a
sharp boundary between diabetes-related
and -unrelated complications remains
an important aspect. This applies, for in-
stance, to tumors, injury/poisoning, or
psychiatric and psychological illnesses.
As for the injuries, it cannot be ruled
out that peripheral neuropathy and
foot deformities are associated with in-
creased risk of injuries. This is why no
diseases beyond type 1 and other diabe-
tes were excluded here. In addition, the
relatively large sample size already en-
sures the stability of the results and that
certain groups are not overrepresented
by chance.
Summary and Implications
Type 2 diabetes complications have a sig-
niﬁcant impact on total health care costs
in the SHI system, with varying size de-
pendent on age, sex, and type of compli-
cation. Our comprehensive estimates
may further inform diabetes models and
support politicians and health care actors
in evaluating the optimal resource alloca-
tion across differentpreventionand inter-
vention programs for themanagement of
type 2 diabetes complications. For high-
frequency complications, it is of particular
interest for future studies to investigate a
deeper analysis of interactions between
complications and the importance of the
severity of complications. It is also to be
expected that this study will motivate fu-
ture research in the ﬁeld of diabetesmod-
eling in Germany.
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I. Statistical appendix The basecase model is therefore noted as follows: yij = ȕ0 + ȕ1Z1i + ȕ2lZ2li + ȕ3kZ3ki +ȕ4Z4ij + ȕ5kmZ5kmij + eij  where: i = patient i  j = observation j (quarters 1-12) k = complication k l = age group l m = time period m for a new complication   yij =  outcome/total healthcare costs for patient i and observation j  
ȕ0  = coefficient for the intercept  
ȕ1 = coefficient for sex Z1i = dummy variable for sex (0=’female’, 1=’male’)  
ȕ2l = coefficient for age group l  Z2li = dummy variables for the age group  (l=1:  ‘<50’=1,else 0 , l=2: ‘50-60’=1 else 0, l=3:  ‘60-70’=1 else 0,  l=4:  ‘>80’=1 else 0)  
ȕ3k = coefficient for pre-existing complication k in 2012 Z3ki = for each complication k: 1 if present at baseline, 0 otherwise  
ȕ4= coefficient for death of other reasons  Z4ij = 1 (for death of other reasons), 0 otherwise   
ȕ5km = coefficient for new complication k, in time period m Z5kmij = dummy variables for complication k, in time period m  (m=1: ‘quarter of event*’=1 else 0,  m=2: ‘follow-up quarter’< 1 year’=1 else 0, m=3:  ‘follow-up quarter’>1 year’=1 else 0)   eij = error term for patient i, observation j   * ‘Event’ refers to quarter when the diabetes complication first occurred/started.  
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 II. Tables Table S1: Technical definition of type 2 diabetes  Criteria/ diabetes group ICD*-E11 (IPC) ICD-E11 (OPC) ICD-E10 (IPC) ICD-E10 (OPC) ICD-E14 (IPC) ICD-E14 (OPC) OAD† DMP type 2 (1) Type 2  25 $1' 0    AND 0     
  $1' 0    AND 0     AND 25    
  $1' 0    AND 0            AND (Yes OR Yes) 
(2) Unclear with type 2 indication 25 $1' 25      AND (Yes OR Yes) (3) Unspecified with type 2 indication 0   AND 0    AND 0   AND 0     AND AND AND (Yes OR Yes) * E10, type 1 diabetes; E11, type 2 diabetes, E14, unspecified diabetes. † At least one prescription of oral antidiabetics in 2012. Abbrevations: DMP, disease management program; ICD, international classification of diseases; ipc, inpatient care; OAD, oral antidiabetic drugs; opc, outpatient care.     
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Table S2: Identification of relevant complications and events based on ICD-10-GM, OPS- and EBM-codes (1-13) Microvascular complications ICD-, OPS- or EBM-codes Eye complications  Retinopathy ICD-codes E10-E14.3- (diabetes with eye complications), H36.0 (diabetic retinopathy), H35.0 (background retinopathy and retinal vascular changes), H35.2 (other proliferative retinopathy) Blindness in one or two eyes ICD-codes H54.0 (blindness, both eyes), H54.4 (blindness, one eye) Renal complications  Renal insufficiency  E11.2- (or E14.2-) (diabetes with renal complications), ICD-codes N17 (acute renal failure), N18 (chronic renal failure, without N18.5), N19 (not other specified renal failure) ESRD  ICD-code N18.5 (terminal renal insufficiency) 
Æ with or without dialysis ICD-codes Z49 (dialysis), Z99.2 (long-term dialysis in renal insufficiency) OPS-codes 8-854 (hemodialysis), 8-855 (hemodiafiltration), 8-857 (peritoneal dialysis), 8-85a (dialysis after failed kidney transplant)  EBM-codes 13602-13622 w/o 13621 (dialysis fees), 40815-40838 (material cost fee) Neuropathic complications  Diabetic foot syndrome (with polyneuropathy and peripheral angiopathy) ICD-codes E10-E14.74 and .75 (diabetes with multiple complications, with diabetic foot syndrome)  or ICD-code for peripheral neuropathy G63.2 (diabetic polyneuropathy) + one of the ICD-codes for PVD: E11.5 (or E14.5) (diabetes with peripheral vascular complications), I70.2 (atherosclerosis of extremities), I73.9 (peripheral vascular disease, not other specified), I79.2 (diabetic peripheral angiopathy), R02 (gangrene)  or 
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EBM-code 02311 (treatment of diabetic foot) Amputation of lower extremities  OPS-codes 5-864 (amputation of lower extremity), 5-865 (amputation of the foot) Macrovascular complications  Cardiovascular complications  Angina pectoris ICD-code I20 (angina pectoris) Chronic heart failure (CHF) ICD-codes I50 (heart failure) , I11.0 (hypertensive heart disease with heart failure), I13.0 (hypertensive heart and chronic kidney disease with heart failure), I13.2 (Hypertensive heart and chronic kidney disease with heart failure and with end stage renal disease) Myocardial infarction/cardiac arrest (non-fatal event) ICD-codes I21 (acute myocardial infarction), I46.0 or .9 (cardiac arrest)  Myocardial infarction/cardiac arrest (fatal event) In addition, see hospital death Other IHD (non-fatal event) ICD-codes I22 (recurrent myocardial infarction), I24 (other acute ischemic heart disease), I25 (chronic ischemic heart disease) Other IHD (fatal event) In addition, see hospital death Cerebrovascular complications  Stroke* (non-fatal event) ICD-codes I60 (subarachnoidal haemorrhage), I61 (intracerebral bleeding), I62 (other non-traumatic intracranial bleeding), I63 (brain infarction), I64 (stroke) Stroke (fatal event) In addition, see hospital death Other events/death  Hospital death Reason for discharge is death Death due to other reasons (including unknown causes) Reason for termination of membership due to death * Stroke includes bleeding inside the brain (hemorrhagic stroke).  Abbreviations: CHF, chronic heart failure; EBM, uniform value scale for outpatient services; ESRD, end-stage renal disease; GM, german modification; ICD, International Classification of Diseases; IHD, ischemic heart disease; OPS, operation procedure codes; PVD, peripheral vascular disease.   
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Table S3: Identification of risk factors and antidiabetic treatment based on ICD-10-GM and ATC-codes Risk factor  ICD-codes Derailed diabetes (derailment of glucose metabolism) E10-E14 plus 1, 3 or 5 as fifth digit Diabetes without complications E10-E14 plus 9 as fourth digit Hypertension I10-I15 Hazardous alcohol consumption or smoking F10 (Alcohol related disorders), F17 (Nicotine dependence) Depression F32 (single depressive episode), F33 (recurrent depressive disorder), F34 (persistent affective disorder) Obesity E66  Cancer C00-C99 Sleeping disorder G47 (sleep disorders), F51 (sleep disorders not due to a substance or known physiological condition) Antidiabetic treatment ATC-codes Antidiabetic treatment type No antidiabetics, OAD alone (ATC-code A10B), insulin+OAD (A10A and A10B) or insulin alone (A10A) Abbreviations: ATC, anatomical therapeutic chemical; GM, german modification; ICD, International Classification of Diseases; OAD, oral antidiabetics. 
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Table S4: Quality assurance activities (December 2016-March 2017) Quality aspect Observed, n Activity Inpatient care   No or zero total payments 5057 and 221 inpatient and outpatient hospital cases Cases were deleted, patients remain included Negative total payments 5 cases Cross-checked with sum of invoice values, otherwise cut to zero Implausible length of stay (>365 days) compared to the amount of payment 1 case Not necessary Incorrect discharge reason death 1 case Corrected Hospital visits abroad 945 cases Those cases remain included Pharmaceuticals   Date of prescription after date of handling by the pharmacy No - Charged costs after death Yes, 822 observations (781 cases) Charged costs after the quarter of death are not considered  
SUPPLEMENTARY DATA 
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Table S5: Calculation of the adapted Diabetes Complication Severity Index (aDCSI) based on ICD-10-GM [further adapted from (10)] Complication ICD-9-CM aDCSI Score* ICD-10-GM Retinopathy    Diabetic ophthalmologic disease 250.5x Ɣ E10-E14.3-, H36.0 Background retinopathy 362.01 Ɣ E10-E14.3 Other retinopathy 362.1 Ɣ H35.0 Retinal edema 362.83 Ɣ H35.8 Clinically Significant Macular Edema (CSME) 362.53 Ɣ H35.3 Other retinal disorders 362.81, 621.82 Ɣ H35.6, H35.8 Proliferative retinopathy 362.02 ƔƔ H35.2 Retinal detachment 361.xx ƔƔ H33 Blindness 369.xx .00-.99 ƔƔ H54 Vitreous hemorrhage 379.23 ƔƔ H43.1 Nephropathy    Diabetic nephropathy 250.4 Ɣ E10-E14.2- Acute glomerulonephritis 580 Ɣ N00 Nephrotic syndrome 581 Ɣ N04 Hypertension, nephrosis 581.81 Ɣ N08 Chronic glomerulonephritis 582 Ɣ N03 Nephritis/nephropathy 583 Ɣ N05, N08, N17 Chronic renal failure 585 ƔƔ N18 Rental failure, not otherwise specified 586 ƔƔ N19 Renal insufficiency 593.9 ƔƔ N28.9 Neuropathy    Diabetic neuropathy 250.6, 356.9 Ɣ E10-E14.4-, G60.9 Amyotrophy 358.1 Ɣ G73.0, G73.3 Cranial nerve palsy 951.0, 951.1, 951.3 Ɣ S04.1, S04.2 Mononeuropathy 354.0-355.9 Ɣ G56-G59 Charcot’s anthropathy 713.5 Ɣ M14.6 Polyneuropathy 357.2 Ɣ G62, G63.2 Cerebrovascular    Transient ischemic attack (TIA) 435 Ɣ G45 Stroke 431, 433, 434, 436 ƔƔ I61, I63, I66, I67 Cardiovascular    Atherosclerosis 440.xx Ɣ I70 
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Other ischemic heart disease (IHD) 411 Ɣ I24 Angina pectoris 413 Ɣ I20 Other chronic IHD 414 Ɣ I25 Myocardial infarction 410 ƔƔ I21 Ventricular fibrillation, arrest 427.1, 427.3 ƔƔ I47.2, I48 Atrial fibrillation, arrest 427.4, 427.5 ƔƔ I49.0 Other atherosclerotic cardiovascular disease (ASCVD) 429.2 Ɣ I25.1 Old myocardial infarction 412 ƔƔ I25.2 Heart failure 428 ƔƔ I50 Atherosclerosis, severe 440.23, 440.24 ƔƔ I70.24, I70.25 Aortic aneurysm/dissection 441 ƔƔ I71 Peripheral vascular disease (PVD)    Diabetic PVD 250.7 Ɣ E10-E14.5- Other aneurysm, lower extremities (LE) 442.3 Ɣ I72.4 PVD 443.81, 443.9 Ɣ I79.2/8, I73.9 Foot wound + complication 892.1 Ɣ S91 Claudication, intermittent 443.9 Ɣ I73.9 Embolism/thrombosis (LE) 444.22 ƔƔ I74.3 Gangrene 785.4 ƔƔ I96 Gas gangrene 0.4 ƔƔ A48.0 Ulcer of lower limbs 707.1 ƔƔ L97 Metabolic    Ketoacidosis 250.1 ƔƔ E10-E14.1 Hyperosmolar  250.2 ƔƔ E10-E14.0 Other coma 250.3 ƔƔ E10-E14.0 * Seven complications which in each case can be rated with 0-2 points (except for neuropathy), thus the total score ranges from 0-13. 
 Abbreviations: aDSCI, adapted Diabetes Complications Severity Index, GM, german modification; ICD, International Classification of Diseases; LE, lower extremities. 
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Table S6: Adapted Diabetes Complication Severity Index (aDCSI) in the population by age and sex (at baseline) Sex Age group N Mean Std Dev Minimum Maximum Male <50 yrs 16374 0.6 1.1 0 10 50-59 yrs 40320 1.1 1.4 0 11 60-69 yrs 61142 1.7 1.7 0 11 70-79 yrs 65336 2.5 2.0 0 12 >80 yrs 17038 3.3 2.1 0 11 Female <50 yrs 10738 0.5 1.0 0 8 50-59 yrs 21056 0.9 1.2 0 9 60-69 yrs 32520 1.3 1.5 0 10 70-79 yrs 37265 2.0 1.8 0 11 >80 yrs 14431 2.8 2.0 0 12 Abbreviations: aDCSI, adapted Diabetes Complications Severity Index; std dev, standard deviation; yrs, years. 
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Table S7: Effects of acute events and chronic type 2 diabetes complications on total costs in GEE normal regression considering interactions* with age and sex * All three-fold interactions of complications with age and sex are considered here, except for rare complications with low incidences (amputation, blindness, ESRD, fatal MI, fatal stroke, fatal IHD). Here the interaction gender x complication is considered though. † Due to statistical reasons, it was not differentiated between the follow-up period <1 year and >1 year. Abbreviations: CHF, chronic heart failure; ESRD, end-stage renal disease; IHD, ischemic heart disease; MI, myocardial infarction; QTR, quarter. Parameter Manifestations Estimate Standard Error (SE) p Value Intercept       762.9 9.4 <.0001 Age group <50     -12.7 19.4 0.5127 Age group 50-59     -40.7 13.3 0.0022 Age group 60-69     -46.8 12.3 0.0001 Age group >80     -165.9 15.4 <.0001 Age group 70-79     0.0 0.0 . Gender Male     -35.1 11.5 0.0023 Gender Female     0.0 0.0 . Foot   Qtr of event     570.8 71.3 <.0001 Foot   Follow-up qtr †     324.5 38.0 <.0001 Foot   No     0.0 0.0 . Amputation Qtr of event     13074.1 851.1 <.0001 Amputation Follow-up qtr     2498.2 692.4 0.0003 Amputation No     0.0 0.0 . Retinopathy   Qtr of event     -20.1 45.8 0.6599 Retinopathy   Follow-up qtr     35.6 35.4 0.3145 Retinopathy   No     0.0 0.0 . Blindness Qtr of event     2573.5 353.0 <.0001 Blindness Follow-up qtr     524.0 95.0 <.0001 Blindness No     0.0 0.0 . Nephropathy Qtr of event     2784.8 115.4 <.0001 Nephropathy Follow-up qtr     625.4 40.0 <.0001 Nephropathy No     0.0 0.0 . ESRD Qtr of event     17349.1 1051.1 <.0001 ESRD Follow-up qtr     4176.2 294.2 <.0001 ESRD No     0.0 0.0 . Stroke. nonfatal Qtr of event     9197.1 423.2 <.0001 Stroke. nonfatal Follow-up qtr     1688.0 154.6 <.0001 Stroke. nonfatal No     0.0 0.0 . Stroke. fatal Qtr of event     9387.2 1059.0 <.0001 Stroke. fatal No     0.0 0.0 . Myocardia linfarction. nonfatal Qtr of event     7848.1 569.1 <.0001 Myocardia linfarction. nonfatal Follow-up qtr     773.6 202.6 0.0001 Myocardia linfarction. nonfatal No     0.0 0.0 . Myocardial infarction. fatal Qtr of event     4677.9 686.6 <.0001 
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Parameter Manifestations Estimate Standard Error (SE) p Value Myocardial infarction. fatal No     0.0 0.0 . Other IHD, nonfatal Qtr of event     5040.1 428.2 <.0001 Other IHD, nonfatal Follow-up qtr     476.2 156.7 0.0024 Other IHD, nonfatal No     0.0 0.0 . IHD. fatal Qtr of event     8248.2 3335.7 0.0134 IHD. fatal No     0.0 0.0 . Angina pectoris  Qtr of event     1803.1 154.7 <.0001 Angina pectoris  Follow-up qtr     191.7 61.9 0.0019 Angina pectoris  No     0.0 0.0 . CHF   Qtr of event     3345.3 139.5 <.0001 CHF   Follow-up qtr     717.7 44.1 <.0001 CHF   No     0.0 0.0 . Death for other reasons Qtr of event     5621.2 124.7 <.0001 Death for other reasons No     0.0 0.0 . History of foot complications Yes     369.6 13.9 <.0001 History of foot complications No     0.0 0.0 . History of amputation Yes     2004.1 171.7 <.0001 History of amputation No     0.0 0.0 . History of retinopathy Yes     62.1 9.3 <.0001 History of retinopathy No     0.0 0.0 . History of blindness Yes     198.8 47.6 <.0001 History of blindness No     0.0 0.0 . History of nephropathy Yes     407.5 11.2 <.0001 History of nephropathy No     0.0 0.0 . History of ESRD Yes     6883.0 160.4 <.0001 History of ESRD No     0.0 0.0 . History of stroke Yes     626.7 46.4 <.0001 History of stroke No     0.0 0.0 . History of MI Yes     48.1 45.2 0.2864 History of MI No     0.0 0.0 . History of IHD Yes     555.0 25.3 <.0001 History of IHD No     0.0 0.0 . History of angina  Yes     -12.5 19.1 0.512 History of angina  No     0.0 0.0 . History of CHF Yes     529.2 12.9 <.0001 History of CHF No     0.0 0.0 . Age group*gender <50 Male   -189.7 23.1 <.0001 Age group*gender <50 Female   0.0 0.0 . Age group*gender 50-59 Male   -113.1 17.5 <.0001 Age group*gender 50-59 Female   0.0 0.0 . Age group*gender 60-69 Male   -37.4 16.1 0.0203 Age group*gender 60-69 Female   0.0 0.0 . Age group*gender >80 Male   77.4 22.3 0.0005 Age group*gender >80 Female   0.0 0.0 . 
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Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender 70-79 Male   0.0 0.0 . Age group*gender 70-79 Female   0.0 0.0 . Age group*gender*MI <50 Male Qtr of event -562.9 1010.7 0.5776 Age group*gender*MI <50 Male Follow-up qtr -107.7 372.9 0.7726 Age group*gender*MI <50 Male No 0.0 0.0 . Age group*gender*MI <50 Female Qtr of event -2510.5 1337.2 0.0605 Age group*gender*MI <50 Female Follow-up qtr -131.6 551.7 0.8115 Age group*gender*MI <50 Female No 0.0 0.0 . Age group*gender*MI 50-60 Male Qtr of event -786.5 740.5 0.2882 Age group*gender*MI 50-60 Male Follow-up qtr -275.5 266.7 0.3015 Age group*gender*MI 50-60 Male No 0.0 0.0 . Age group*gender*MI 50-60 Female Qtr of event -1449.2 803.7 0.0714 Age group*gender*MI 50-60 Female Follow-up qtr -368.6 312.8 0.2386 Age group*gender*MI 50-60 Female No 0.0 0.0 . Age group*gender*MI 60-70 Male Qtr of event -6.2 644.0 0.9924 Age group*gender*MI 60-70 Male Follow-up qtr -261.9 240.3 0.2758 Age group*gender*MI 60-70 Male No 0.0 0.0 . Age group*gender*MI 60-70 Female Qtr of event -1629.3 693.7 0.0188 Age group*gender*MI 60-70 Female Follow-up qtr 64.8 343.8 0.8505 Age group*gender*MI 60-70 Female No 0.0 0.0 . Age group*gender*MI >80 Male Qtr of event -1714.3 693.7 0.0135 Age group*gender*MI >80 Male Follow-up qtr -380.6 266.2 0.1528 Age group*gender*MI >80 Male No 0.0 0.0 . Age group*gender*MI >80 Female Qtr of event -2543.3 670.8 0.0001 Age group*gender*MI >80 Female Follow-up qtr -464.1 276.0 0.0926 Age group*gender*MI >80 Female No 0.0 0.0 . Age group*gender*MI 70-80 Male Qtr of event -31.0 651.8 0.9621 Age group*gender*MI 70-80 Male Follow-up qtr -107.2 227.6 0.6378 Age group*gender*MI 70-80 Male No 0.0 0.0 . Age group*gender*MI 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*MI 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*MI 70-80 Female No 0.0 0.0 . Age group*gender*MI, fatal Male Qtr of event   4472.4 1420.9 0.0016 Age group*gender*MI, fatal Male No   0.0 0.0 . Age group*gender*MI, fatal Female Qtr of event   0.0 0.0 . Age group*gender*MI, fatal Female No   0.0 0.0 . Gender*IHD, fatal Male Qtr of event   14596.8 7244.9 0.0439 Gender*IHD, fatal Male No   0.0 0.0 . Gender*IHD, fatal Female Qtr of event   0.0 0.0 . Gender*IHD, fatal Female No   0.0 0.0 . Age group*gender*IHD <50 Male Qtr of event 153.5 793.4 0.8466 Age group*gender*IHD <50 Male Follow-up qtr -481.6 260.6 0.0646 Age group*gender*IHD <50 Male No 0.0 0.0 . Age group*gender*IHD <50 Female Qtr of event -681.3 1093.2 0.5332 
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Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender*IHD <50 Female Follow-up qtr 546.6 963.5 0.5705 Age group*gender*IHD <50 Female No 0.0 0.0 . Age group*gender*IHD 50-60 Male Qtr of event 1182.4 753.1 0.1164 Age group*gender*IHD 50-60 Male Follow-up qtr 112.1 258.5 0.6645 Age group*gender*IHD 50-60 Male No 0.0 0.0 . Age group*gender*IHD 50-60 Female Qtr of event 2588.4 1316.3 0.0493 Age group*gender*IHD 50-60 Female Follow-up qtr -81.1 297.8 0.7855 Age group*gender*IHD 50-60 Female No 0.0 0.0 . Age group*gender*IHD 60-70 Male Qtr of event 1010.9 506.7 0.046 Age group*gender*IHD 60-70 Male Follow-up qtr -29.2 193.7 0.8801 Age group*gender*IHD 60-70 Male No 0.0 0.0 . Age group*gender*IHD 60-70 Female Qtr of event 377.7 885.7 0.6698 Age group*gender*IHD 60-70 Female Follow-up qtr -288.7 204.2 0.1574 Age group*gender*IHD 60-70 Female No 0.0 0.0 . Age group*gender*IHD >80 Male Qtr of event 94.1 577.8 0.8706 Age group*gender*IHD >80 Male Follow-up qtr -69.2 245.3 0.7779 Age group*gender*IHD >80 Male No 0.0 0.0 . Age group*gender*IHD >80 Female Qtr of event -150.3 761.0 0.8434 Age group*gender*IHD >80 Female Follow-up qtr 134.8 298.0 0.6509 Age group*gender*IHD >80 Female No 0.0 0.0 . Age group*gender*IHD 70-80 Male Qtr of event 874.8 467.0 0.061 Age group*gender*IHD 70-80 Male Follow-up qtr -278.3 172.5 0.1067 Age group*gender*IHD 70-80 Male No 0.0 0.0 . Age group*gender*IHD 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*IHD 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*IHD 70-80 Female No 0.0 0.0 . Age group*gender*stroke <50 Male Qtr of event 89.0 1151.4 0.9384 Age group*gender*stroke <50 Male Follow-up qtr -224.0 532.7 0.6741 Age group*gender*stroke <50 Male No 0.0 0.0 . Age group*gender*stroke <50 Female Qtr of event 935.0 1992.7 0.6389 Age group*gender*stroke <50 Female Follow-up qtr 6092.3 4133.8 0.1405 Age group*gender*stroke <50 Female No 0.0 0.0 . Age group*gender*stroke 50-60 Male Qtr of event 22.2 992.9 0.9822 Age group*gender*stroke 50-60 Male Follow-up qtr -392.5 246.0 0.1106 Age group*gender*stroke 50-60 Male No 0.0 0.0 . Age group*gender*stroke 50-60 Female Qtr of event -690.8 1282.0 0.59 Age group*gender*stroke 50-60 Female Follow-up qtr 1098.7 782.7 0.1604 Age group*gender*stroke 50-60 Female No 0.0 0.0 . Age group*gender*stroke 60-70 Male Qtr of event 102.3 583.7 0.8608 Age group*gender*stroke 60-70 Male Follow-up qtr 185.8 225.5 0.4099 Age group*gender*stroke 60-70 Male No 0.0 0.0 . Age group*gender*stroke 60-70 Female Qtr of event 80.8 685.6 0.9062 Age group*gender*stroke 60-70 Female Follow-up qtr 229.4 299.8 0.4442 Age group*gender*stroke 60-70 Female No 0.0 0.0 . 
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Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender*stroke >80 Male Qtr of event -508.9 560.5 0.3639 Age group*gender*stroke >80 Male Follow-up qtr -823.9 207.7 <.0001 Age group*gender*stroke >80 Male No 0.0 0.0 . Age group*gender*stroke >80 Female Qtr of event -1339.7 536.2 0.0125 Age group*gender*stroke >80 Female Follow-up qtr -790.3 198.0 <.0001 Age group*gender*stroke >80 Female No 0.0 0.0 . Age group*gender*stroke 70-80 Male Qtr of event -136.2 502.2 0.7862 Age group*gender*stroke 70-80 Male Follow-up qtr -75.6 188.6 0.6884 Age group*gender*stroke 70-80 Male No 0.0 0.0 . Age group*gender*stroke 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*stroke 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*stroke 70-80 Female No 0.0 0.0 . Age group*gender*stroke, fatal Male Qtr of event   2013.3 1699.3 0.2361 Age group*gender*stroke, fatal Male No   0.0 0.0 . Age group*gender*stroke, fatal Female Qtr of event   0.0 0.0 . Age group*gender*stroke, fatal Female No   0.0 0.0 . Age group*gender*CHF <50 Male Qtr of event -28.3 658.0 0.9657 Age group*gender*CHF <50 Male Follow-up qtr 186.3 207.8 0.3698 Age group*gender*CHF <50 Male No 0.0 0.0 . Age group*gender*CHF <50 Female Qtr of event -280.2 592.7 0.6363 Age group*gender*CHF <50 Female Follow-up qtr 256.0 243.1 0.2923 Age group*gender*CHF <50 Female No 0.0 0.0 . Age group*gender*CHF 50-60 Male Qtr of event 2.3 338.2 0.9946 Age group*gender*CHF 50-60 Male Follow-up qtr 107.8 92.8 0.2451 Age group*gender*CHF 50-60 Male No 0.0 0.0 . Age group*gender*CHF 50-60 Female Qtr of event -348.9 344.8 0.3116 Age group*gender*CHF 50-60 Female Follow-up qtr -47.4 119.9 0.6928 Age group*gender*CHF 50-60 Female No 0.0 0.0 . Age group*gender*CHF 60-70 Male Qtr of event -216.6 188.8 0.2513 Age group*gender*CHF 60-70 Male Follow-up qtr 62.8 69.7 0.3672 Age group*gender*CHF 60-70 Male No 0.0 0.0 . Age group*gender*CHF 60-70 Female Qtr of event -222.9 230.9 0.3345 Age group*gender*CHF 60-70 Female Follow-up qtr 115.5 80.1 0.1491 Age group*gender*CHF 60-70 Female No 0.0 0.0 . Age group*gender*CHF >80 Male Qtr of event -450.4 204.4 0.0275 Age group*gender*CHF >80 Male Follow-up qtr -72.5 72.3 0.3163 Age group*gender*CHF >80 Male No 0.0 0.0 . Age group*gender*CHF >80 Female Qtr of event -624.6 189.8 0.001 Age group*gender*CHF >80 Female Follow-up qtr -289.4 64.0 <.0001 Age group*gender*CHF >80 Female No 0.0 0.0 . Age group*gender*CHF 70-80 Male Qtr of event 144.4 172.6 0.4028 Age group*gender*CHF 70-80 Male Follow-up qtr 48.7 56.5 0.3885 Age group*gender*CHF 70-80 Male No 0.0 0.0 . Age group*gender*CHF 70-80 Female Qtr of event 0.0 0.0 . 
©2018 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1763/-/DC1 
SUPPLEMENTARY DATA 
Supplementary appendix to article 1
53
 
103 
 
Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender*CHF 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*CHF 70-80 Female No 0.0 0.0 . Age group*gender*foot <50 Male Qtr of event 187.6 425.0 0.6589 Age group*gender*foot <50 Male Follow-up qtr -21.8 71.4 0.7601 Age group*gender*foot <50 Male No 0.0 0.0 . Age group*gender*foot <50 Female Qtr of event 305.7 237.2 0.1974 Age group*gender*foot <50 Female Follow-up qtr 252.6 200.7 0.2081 Age group*gender*foot <50 Female No 0.0 0.0 . Age group*gender*foot 50-60 Male Qtr of event -24.7 98.5 0.802 Age group*gender*foot 50-60 Male Follow-up qtr 67.0 59.5 0.26 Age group*gender*foot 50-60 Male No 0.0 0.0 . Age group*gender*foot 50-60 Female Qtr of event -93.0 94.6 0.326 Age group*gender*foot 50-60 Female Follow-up qtr 13.2 60.9 0.828 Age group*gender*foot 50-60 Female No 0.0 0.0 . Age group*gender*foot 60-70 Male Qtr of event -63.9 89.9 0.477 Age group*gender*foot 60-70 Male Follow-up qtr 40.5 54.4 0.4558 Age group*gender*foot 60-70 Male No 0.0 0.0 . Age group*gender*foot 60-70 Female Qtr of event -37.3 95.7 0.697 Age group*gender*foot 60-70 Female Follow-up qtr 58.6 58.6 0.3179 Age group*gender*foot 60-70 Female No 0.0 0.0 . Age group*gender*foot >80 Male Qtr of event 377.4 133.1 0.0046 Age group*gender*foot >80 Male Follow-up qtr -51.5 71.4 0.4703 Age group*gender*foot >80 Male No 0.0 0.0 . Age group*gender*foot >80 Female Qtr of event 208.9 123.0 0.0894 Age group*gender*foot >80 Female Follow-up qtr -157.2 63.1 0.0127 Age group*gender*foot >80 Female No 0.0 0.0 . Age group*gender*foot 70-80 Male Qtr of event 190.1 99.6 0.0563 Age group*gender*foot 70-80 Male Follow-up qtr 45.9 51.0 0.3681 Age group*gender*foot 70-80 Male No 0.0 0.0 . Age group*gender*foot 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*foot 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*foot 70-80 Female No 0.0 0.0 . Age group*gender*retinopathy <50 Male Qtr of event -11.4 74.8 0.8787 Age group*gender*retinopathy <50 Male Follow-up qtr 73.9 106.7 0.4887 Age group*gender*retinopathy <50 Male No 0.0 0.0 . Age group*gender*retinopathy <50 Female Qtr of event 20.6 82.2 0.8018 Age group*gender*retinopathy <50 Female Follow-up qtr 72.3 78.0 0.3534 Age group*gender*retinopathy <50 Female No 0.0 0.0 . Age group*gender*retinopathy 50-60 Male Qtr of event 95.6 64.7 0.1394 Age group*gender*retinopathy 50-60 Male Follow-up qtr 55.6 51.4 0.2794 Age group*gender*retinopathy 50-60 Male No 0.0 0.0 . Age group*gender*retinopathy 50-60 Female Qtr of event 212.5 87.9 0.0156 Age group*gender*retinopathy 50-60 Female Follow-up qtr 73.7 54.1 0.1729 Age group*gender*retinopathy 50-60 Female No 0.0 0.0 . 
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Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender*retinopathy 60-70 Male Qtr of event 23.9 55.8 0.6686 Age group*gender*retinopathy 60-70 Male Follow-up qtr -61.9 44.9 0.1684 Age group*gender*retinopathy 60-70 Male No 0.0 0.0 . Age group*gender*retinopathy 60-70 Female Qtr of event 44.3 62.4 0.4775 Age group*gender*retinopathy 60-70 Female Follow-up qtr -28.1 47.2 0.552 Age group*gender*retinopathy 60-70 Female No 0.0 0.0 . Age group*gender*retinopathy >80 Male Qtr of event 136.2 105.1 0.1949 Age group*gender*retinopathy >80 Male Follow-up qtr -6.6 72.2 0.9269 Age group*gender*retinopathy >80 Male No 0.0 0.0 . Age group*gender*retinopathy >80 Female Qtr of event 178.3 94.3 0.0587 Age group*gender*retinopathy >80 Female Follow-up qtr 59.0 76.2 0.4383 Age group*gender*retinopathy >80 Female No 0.0 0.0 . Age group*gender*retinopathy 70-80 Male Qtr of event -33.8 58.7 0.5644 Age group*gender*retinopathy 70-80 Male Follow-up qtr -49.1 46.0 0.2854 Age group*gender*retinopathy 70-80 Male No 0.0 0.0 . Age group*gender*retinopathy 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*retinopathy 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*retinopathy 70-80 Female No 0.0 0.0 . Age group*gender*nephropathy <50 Male Qtr of event -753.8 465.0 0.105 Age group*gender*nephropathy <50 Male Follow-up qtr -240.0 97.0 0.0134 Age group*gender*nephropathy <50 Male No 0.0 0.0 . Age group*gender*nephropathy <50 Female Qtr of event -1430.6 330.7 <.0001 Age group*gender*nephropathy <50 Female Follow-up qtr -159.8 138.0 0.2469 Age group*gender*nephropathy <50 Female No 0.0 0.0 . Age group*gender*nephropathy 50-60 Male Qtr of event -478.2 218.7 0.0287 Age group*gender*nephropathy 50-60 Male Follow-up qtr 28.1 73.0 0.7 Age group*gender*nephropathy 50-60 Male No 0.0 0.0 . Age group*gender*nephropathy 50-60 Female Qtr of event -945.8 214.9 <.0001 Age group*gender*nephropathy 50-60 Female Follow-up qtr -16.8 89.4 0.8506 Age group*gender*nephropathy 50-60 Female No 0.0 0.0 . Age group*gender*nephropathy 60-70 Male Qtr of event 177.8 187.0 0.3415 Age group*gender*nephropathy 60-70 Male Follow-up qtr 122.3 60.8 0.0442 Age group*gender*nephropathy 60-70 Male No 0.0 0.0 . Age group*gender*nephropathy 60-70 Female Qtr of event -593.7 178.5 0.0009 Age group*gender*nephropathy 60-70 Female Follow-up qtr -86.4 64.0 0.1771 Age group*gender*nephropathy 60-70 Female No 0.0 0.0 . Age group*gender*nephropathy >80 Male Qtr of event 171.8 192.6 0.3724 Age group*gender*nephropathy >80 Male Follow-up qtr -164.8 64.3 0.0103 Age group*gender*nephropathy >80 Male No 0.0 0.0 . Age group*gender*nephropathy >80 Female Qtr of event 96.9 176.0 0.5818 Age group*gender*nephropathy >80 Female Follow-up qtr -104.3 60.2 0.0834 Age group*gender*nephropathy >80 Female No 0.0 0.0 . Age group*gender*nephropathy 70-80 Male Qtr of event 55.5 145.4 0.7027 Age group*gender*nephropathy 70-80 Male Follow-up qtr -71.8 51.1 0.1595 
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Parameter Manifestations Estimate Standard Error (SE) p Value Age group*gender*nephropathy 70-80 Male No 0.0 0.0 . Age group*gender*nephropathy 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*nephropathy 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*nephropathy 70-80 Female No 0.0 0.0 . Age group*gender*angina <50 Male Qtr of event -79.6 279.5 0.7758 Age group*gender*angina <50 Male Follow-up qtr 215.6 227.0 0.3421 Age group*gender*angina <50 Male No 0.0 0.0 . Age group*gender*angina <50 Female Qtr of event -597.4 272.4 0.0283 Age group*gender*angina <50 Female Follow-up qtr 59.5 155.4 0.7017 Age group*gender*angina <50 Female No 0.0 0.0 . Age group*gender*angina 50-60 Male Qtr of event 80.7 209.3 0.6998 Age group*gender*angina 50-60 Male Follow-up qtr -25.6 105.7 0.809 Age group*gender*angina 50-60 Male No 0.0 0.0 . Age group*gender*angina 50-60 Female Qtr of event -636.4 215.2 0.0031 Age group*gender*angina 50-60 Female Follow-up qtr -80.0 106.5 0.4526 Age group*gender*angina 50-60 Female No 0.0 0.0 . Age group*gender*angina 60-70 Male Qtr of event 433.2 190.0 0.0226 Age group*gender*angina 60-70 Male Follow-up qtr -111.4 80.1 0.1643 Age group*gender*angina 60-70 Male No 0.0 0.0 . Age group*gender*angina 60-70 Female Qtr of event -160.5 208.1 0.4405 Age group*gender*angina 60-70 Female Follow-up qtr -48.1 89.9 0.5926 Age group*gender*angina 60-70 Female No 0.0 0.0 . Age group*gender*angina >80 Male Qtr of event 469.5 260.6 0.0716 Age group*gender*angina >80 Male Follow-up qtr 46.1 111.5 0.6793 Age group*gender*angina >80 Male No 0.0 0.0 . Age group*gender*angina >80 Female Qtr of event 5.7 268.3 0.9831 Age group*gender*angina >80 Female Follow-up qtr 13.0 109.9 0.906 Age group*gender*angina >80 Female No 0.0 0.0 . Age group*gender*angina 70-80 Male Qtr of event 491.7 186.8 0.0085 Age group*gender*angina 70-80 Male Follow-up qtr 7.6 77.1 0.9217 Age group*gender*angina 70-80 Male No 0.0 0.0 . Age group*gender*angina 70-80 Female Qtr of event 0.0 0.0 . Age group*gender*angina 70-80 Female Follow-up qtr 0.0 0.0 . Age group*gender*angina 70-80 Female No 0.0 0.0 . Gender*ESRD Male Qtr of event   6340.7 1369.8 <.0001 Gender*ESRD Male Follow-up qtr   1345.7 371.0 0.0003 Gender*ESRD Male No   0.0 0.0 . Gender*ESRD Female Qtr of event   0.0 0.0 . Gender*ESRD Female Follow-up qtr   0.0 0.0 . Gender*ESRD Female No   0.0 0.0 . Gender*blindness Male Qtr of event   -523.9 398.6 0.1888 Gender*blindness Male Follow-up qtr   -178.8 120.2 0.137 Gender*blindness Male No   0.0 0.0 . 
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Parameter Manifestations Estimate Standard Error (SE) p Value Gender*blindness Female Qtr of event   0.0 0.0 . Gender*blindness Female Follow-up qtr   0.0 0.0 . Gender*blindness Female No   0.0 0.0 . Gender*amputation Male Qtr of event   632.8 1019.5 0.5348 Gender*amputation Male Follow-up qtr   -125.3 712.1 0.8603 Gender*amputation Male No   0.0 0.0 . Gender*amputation Female Qtr of event   0.0 0.0 . Gender*amputation Female Follow-up qtr   0.0 0.0 . Gender*amputation Female No   0.0 0.0 .   
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Table S8: Expected total costs per quarter and year for type 2 diabetes patients of varying age and gender*   * All three-fold interactions of complications with age and sex are considered here (see Table S7), except for rare complications with low incidences (amputation, blindness, ESRD, fatal MI, fatal stroke, fatal IHD). Here the interaction gender x complication is considered though. † Due to statistical reasons, it was not differentiated between the follow-up period <1 year and >1 year. ‡ A mean case scenario was assumed to account for the possibility that complications can occur in one of four quarters.  Abbreviations: CHF, chronic heart failure; ESRD, end-stage renal disease; IHD, ischemic heart disease; MI, myocardial infarction; QTR, quarter. Type of complication Age group (in years) Total estimated costs (in €) in the quarter of event (and follow-up quarter†) Annualized total costs (in €) in the year of event‡ (and follow-up year)     Male Female Male Female     Qtr of event Follow-up qtr Qtr of event Follow-up qtr Year of event Follow-up year Year of event Follow-up year 
Foot <50 1,284 828 1,627 1,327 3,314 3,313 4,743 5,309 50-59 1,120 965 1,200 1,060 3,429 3,862 3,873 4,240 60-69 1,150 1,009 1,250 1,099 3,629 4,034 3,972 4,396 70-79 1,489 1,098 1,334 1,087 4,228 4,393 4,109 4,350 >80 1,510 912 1,377 764 3,838 3,649 3,419 3,057 
Amputation <50 14,232 2,898 13,824 3,248 19,368 11,594 19,823 12,994 50-59 14,281 2,947 13,796 3,220 19,562 11,788 19,710 12,882 60-69 14,350 3,017 13,790 3,214 19,841 12,066 19,686 12,857 70-79 14,435 3,101 13,837 3,261 20,178 12,403 19,873 13,045 >80 14,346 3,012 13,671 3,095 19,824 12,049 19,210 12,381 
Retinopathy <50 494 635 751 858 2,235 2,540 3,164 3,433 50-59 649 665 915 832 2,508 2,661 3,245 3,326 60-69 647 617 740 724 2,539 2,469 2,900 2,895 70-79 674 714 743 799 2,837 2,857 3,085 3,194 >80 678 668 755 692 2,640 2,674 2,688 2,767 
Blindness <50 2,575 871 3,324 1,274 4,669 3,483 6,361 5,097 50-59 2,624 919 3,296 1,246 4,864 3,677 6,248 4,985 60-69 2,693 989 3,290 1,240 5,142 3,955 6,224 4,960 70-79 2,777 1,073 3,336 1,287 5,479 4,292 6,411 5,148 >80 2,689 985 3,171 1,121 5,125 3,939 5,748 4,484 
Nephropathy <50 2,557 911 2,104 1,216 4,711 3,644 5,054 4,864 50-59 2,881 1,228 2,561 1,331 5,583 4,910 5,641 5,323 60-69 3,606 1,391 2,907 1,255 6,658 5,565 5,864 5,021 70-79 3,568 1,281 3,548 1,388 6,582 5,126 6,775 5,553 >80 3,519 1,100 3,479 1,118 6,128 4,400 6,052 4,473 
ESRD <50 24,215 6,047 18,099 4,926 34,075 24,189 26,614 19,706 50-59 24,264 6,096 18,071 4,898 34,269 24,384 26,502 19,594 60-69 24,333 6,165 18,065 4,892 34,547 24,662 26,478 19,569 70-79 24,418 6,250 18,112 4,939 34,884 24,999 26,665 19,756 >80 24,329 6,161 17,946 4,773 34,530 24,645 26,002 19,093 
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Type of complication Age group (in years) Total estimated costs (in €) in the quarter of event (and follow-up quarter†) Annualized total costs (in €) in the year of event‡ (and follow-up year)     Male Female Male Female     Qtr of event Follow-up qtr Qtr of event Follow-up qtr Year of event Follow-up year Year of event Follow-up year 
Nonfatal stroke <50 9,812 1,990 10,882 8,531 13,584 7,958 24,804 34,123 50-59 9,793 1,870 9,229 3,509 13,459 7,478 15,575 14,036 60-69 9,943 2,517 9,994 2,634 14,684 10,070 15,018 10,534 70-79 9,789 2,340 9,960 2,451 14,391 9,361 14,781 9,804 >80 9,250 1,504 8,455 1,495 12,465 6,014 11,592 5,979 
Fatal stroke <50 11,926 na 10,137 na 12,765 na 11,263 na 50-59 11,975 na 10,109 na 12,874 na 11,193 na 60-69 12,044 na 10,103 na 13,031 na 11,177 na 70-79 12,128 na 10,150 na 13,220 na 11,295 na >80 12,040 na 9,984 na 13,021 na 10,880 na 
Nonfatal MI <50 7,811 1,191 6,088 1,392 10,386 4,765 9,302 5,569 50-59 7,636 1,072 7,121 1,127 10,105 4,289 9,895 4,509 60-69 8,485 1,155 6,935 1,554 11,184 4,621 10,341 6,218 70-79 8,545 1,394 8,611 1,537 11,728 5,577 12,060 6,146 >80 6,696 1,032 5,902 907 9,203 4,130 8,157 3,626 
Fatal MI <50 9,676 na 5,428 na 10,515 na 6,554 na 50-59 9,724 na 5,400 na 10,624 na 6,483 na 60-69 9,794 na 5,394 na 10,780 na 6,468 na 70-79 9,878 na 5,441 na 10,970 na 6,585 na >80 9,790 na 5,275 na 10,771 na 6,171 na 
Nonfatal IHD <50 5,719 520 5,109 1,773 7,287 2,080 8,894 7,092 50-59 6,796 1,162 8,351 1,117 9,401 4,649 11,110 4,469 60-69 6,695 1,091 6,134 904 9,296 4,362 8,563 3,614 70-79 6,643 926 5,803 1,239 9,123 3,703 8,806 4,957 >80 5,696 1,046 5,487 1,208 8,225 4,186 8,195 4,832 
Fatal IHD <50 23,371 na 8,998 na 24,209 na 10,124 na 50-59 23,419 na 8,970 na 24,319 na 10,054 na 60-69 23,489 na 8,964 na 24,475 na 10,038 na 70-79 23,573 na 9,011 na 24,665 na 10,156 na >80 23,484 na 8,845 na 24,466 na 9,741 na 
Angina pectoris <50 2,249 933 1,956 1,002 4,436 3,731 4,584 4,006 50-59 2,458 740 1,889 834 4,429 2,961 4,223 3,336 60-69 2,880 724 2,359 860 4,931 2,896 4,722 3,439 70-79 3,023 927 2,566 955 5,505 3,709 5,142 3,819 >80 2,835 877 2,406 802 5,110 3,509 4,504 3,207 
CHF <50 3,842 1,430 3,815 1,724 6,775 5,718 7,527 6,896 50-59 3,922 1,400 3,719 1,393 6,882 5,598 6,891 5,570 60-69 3,772 1,424 3,839 1,549 6,874 5,696 7,237 6,197 70-79 4,218 1,494 4,108 1,481 7,551 5,977 7,474 5,923 >80 3,457 1,285 3,318 1,025 6,343 5,139 5,751 4,101 No complication <50 526 750 2,102 3,001 
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Type of complication Age group (in years) Total estimated costs (in €) in the quarter of event (and follow-up quarter†) Annualized total costs (in €) in the year of event‡ (and follow-up year)     Male Female Male Female     Qtr of event Follow-up qtr Qtr of event Follow-up qtr Year of event Follow-up year Year of event Follow-up year 50-59 574 722 2,296 2,889 60-69 644 716 2,574 2,864 70-79 728 763 2,911 3,052 >80 639 597 2,558 2,388   
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Table S9
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 patients†
 
* Cost fac
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d by divid
ing the to
tal costs 
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omplicati
on by the
 total cos
ts in abse
nce of co
mplicatio
ns.  
† The exte
nded mod
el with all
 three-fol
d interact
ions of co
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ns with a
ge and se
x was use
d here (s
ee Table 
S8). 
Abbrevia
tions: CH
F, chronic
 heart fail
ure; ESR
D, end-st
age rena
l disease
; IHD, isc
hemic he
art diseas
e; MI, my
ocardial i
nfarction;
 na, not a
vailable. 
 
Male 
Female 
 Type of complica
tion 
Year of event  (in €) 
Cost Factor 
Cost Factor (UKPDS)
 Follow
- up year (in €) 
Cost Factor 
Cost Factor (UKPDS)
 Year o
f event  (in €) 
Cost Factor 
Cost Factor (UKPDS)
 Follow
-up year (in €
) Cost
 Factor 
Cost Factor (UKPDS)
 
Foot 
4,228 
1.5 
3.9 
4,393 
1.5 
0.6 4
,109 
1.3 
3.2 
4,350 
1.4 
0.5 
Amputat
ion 
20,178 
6.9 
7.9 
12,403 
4.3 
2.8 19
,873 
6.5 
6.9 
13,045 
4.3 
2.6 
Retinopa
thy 
2,837 
1.0 
na 
2,857 
1.0 
na 3,
085 
1.0 
na 
3,194 
1.0 
na 
Blindnes
s 
5,479 
1.9 
2.6 
4,292 
1.5 
1.1 6
,411 
2.1 
2.4 
5,148 
1.7 
1.1 
Nephrop
athy 
6,582 
2.3 
na 
5,126 
1.8 
na 6,
775 
2.2 
na 
5,553 
1.8 
na 
ESRD 
34,884 
12.0 
11.2 
24,999 
8.6 
11.2 2
6,665 
8.7 
9.4 
19,756 
6.5 
9.4 
Non-fata
l stroke 
14,391 
4.9 
5.9 
9,361 
3.2 
1.8 14
,781 
4.8 
5.2 
9,804 
3.2 
1.8 
Fatal stro
ke 
13,220 
4.5 
3.4 
na 
na 
na 11,
295 
3.7 
3.1 
na 
na 
na 
Non-fata
l MI 
11,728 
4.0 
4.9 
5,577 
1.9 
1.8 12
,060 
4.0 
4.3 
6,146 
2.0 
1.7 
Fatal MI 
10,970 
3.8 
2.0 
na 
na 
na 6,
585 
2.2 
1.8 
na 
na 
na 
Non-fata
l IHD 
9,123 
3.1 
7.2 
3,703 
1.3 
1.9 8
,806 
2.9 
6.3 
4,957 
1.6 
1.8 
Fatal IHD
 
24,665 
8.5 
3.2 
na 
na 
na 10,
156 
3.3 
2.9 
na 
na 
na 
Angina p
ectoris 
5,505 
1.9 
na 
3,709 
1.3 
na 5,
142 
1.7 
na 
3,819 
1.3 
na 
CHF 
7,551 
2.6 
3.1 
5,977 
2.1 
2.3 7
,474 
2.4 
2.8 
5,923 
1.9 
2.1 
No comp
lication 
2,911 
1.0 
1.0 
2,911 
1.0 
1.0 3
,052 
1.0 
1.0 
3,052 
1.0 
1.0 
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B. Shares of total healthcare costs by healthcare sector und year   
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Figure S2: Relative cost factor* at time and after the occurrence of acute events or onset of chronic complications in quarterly intervals†  * Cost factor was calculated by dividing total costs in quarter x by mean costs in a quarter of no complications (€703).   † The method of linear interpolation was used between quarterly data points.   A. Diabetic foot  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 41,481 44,689 38,576 33,036 29,488 25,649 21,943 18,083 15,338 12,130 8,999 5,879 2,803  B. Amputation 
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 1,726 1,887 1,510 1,273 1,086 924 764 652 518 413 314 184 94 
©2018 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1763/-/DC1 
SUPPLEMENTARY DATA Supplementary appendix to article 1
64
 
103 
 
C. Retinopathy 
 Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 26,190 30,408 28,564 26,627 24,641 22,463 20,248 18,057 15,779 12,997 10,200 7,296 3,949  D. Blindness
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 1,771 1,949 1,746 1,549 1,383 1,240 1,079 920 765 619 460 303 144 
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E. Nephropathy  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 43,302 47,463 41,028 36,179 31,909 28,018 24,444 20,962 17,535 13,718 10,009 6,589 3,320  F. End-stage renal disease  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 3,470 3,775 2,308 1,874 1,581 1,350 1,137 952 775 606 422 271 114  
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G1. Non-fatal stroke  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 6,628 7,192 6,281 5,452 4,747 4,116 3,499 2,919 2,365 1,869 1,376 848 403  G2. Fatal stroke  
  Time 0 1  2 3 4 5 6 7 8 9 10 11 12 n 686 739  690 632 575 495 415 355 297 228 169 110 53 
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H1. Non-fatal myocardial infarction  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12n 5,168 5,650 4,980 4,408 3,913 3,423 2,866 2,434 1,989 1,553 1,150 773 395  H2. Fatal myocardial infarction  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12n 726 790 716 655 576 502 421 354 282 218 168 123 64 
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I1. Non-fatal other ischemic heart disease  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 5,918 6,345 5,749 5,157 4,557 3,949 3,439 2,892 2,396 1,838 1,321 836 397  I2. Fatal other ischemic heart disease  
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 55 57 53 46 39 35 27 23 20 14 7 5 2  
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J. Angina pectoris 
 Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 14,781 16,491 15,123 13,878 12,683 11,298 9,901 8,552 7,236 5,762 4,336 3,004 1,563  K. Chronic heart failure
  Time 0 1 2 3 4 5 6 7 8 9 10 11 12 n 33,142 36,825 32,378 29,103 26,072 23,093 20,438 17,653 14,725 11,462 8,602 5,728 2,859  
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Abstract
Background In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, 
which leads to increased multimorbidity and economic burden.
Objective The primary aim was to explore diﬀerent strategies that address the economic impact of multiple type 2 diabetes-
related complications and their interactions.
Methods We used a generalized estimating equations approach based on nationwide statutory health insurance data from 
316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 
2015 euros) for type 2 diabetes-related complications and, in addition, explored diﬀerent strategies to assess diabetes-related 
multimorbidity: number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease–dis-
ease interactions of prevalent complications, and interactions between prevalent/incident complications.
Results The increased number of complications was signiﬁcantly associated with higher total costs. Further assessment 
of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., 
end-stage renal disease, amputation) led to signiﬁcant positive eﬀects of interactions on costs, whereas early microvascular 
complications (e.g., retinopathy) caused negative interactions. The chronology of the onset of these complications turned 
out to have an additional impact on the interactions and their eﬀect on total costs.
Conclusions Health economic diabetes models and evaluations of interventions in patients with diabetes-related complica-
tions should pay more attention to the economic eﬀect of speciﬁc disease interactions. Politically, our ﬁndings support the 
development of more integrated diabetes care programs that take better account of multimorbidity. Further observational 
studies are needed to elucidate the shared pathogenic mechanisms of diabetes complications.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-018-0699-1) contains 
supplementary material, which is available to authorized users.
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Care, Techniker Krankenkasse (TK), Hamburg, Germany
Key Points for Decision Makers 
Researchers can choose from various strategies of diﬀer-
ent granularity to assess the economic impact of multiple 
co-occurring diseases and their interactions.
The inclusion of interaction patterns of multiple diabe-
tes-related complications can improve the accuracy of 
model-based cost-eﬀectiveness evaluations.
Longitudinal analysis of real-world claims data revealed 
validity issues in the diagnosis of chronic conditions that 
should be considered in evaluations.
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 K. Kähm et al.
1 Introduction
Type 2 diabetes is not only becoming increasingly prev-
alent worldwide (7% in Germany in 2011), but is also 
emerging as an important comorbidity in daily clinical 
practice [1, 2]. Demographic changes as well as improved 
prognosis of life-threatening and chronic diseases (e.g., 
myocardial infarction [MI], renal insuﬃciency) are con-
tributing to an aging population with diabetes and growing 
multimorbidity. In response to the arising economic chal-
lenges, the term “high-need, high-cost” has been intro-
duced in recent years to characterize a growing group of 
usually older patients who are suﬀering from multiple 
diseases such as diabetes, require multiple medications, 
and tend to have more frequent health behavior problems 
and hospital admissions. What is lacking in the literature 
is a systematic analysis of the impact of diabetes-related 
multimorbidity and underlying heterogeneity from dis-
ease interactions on healthcare costs [3]. Statistically, 
such disease interactions can have a positive or negative 
eﬀect on the outcome variable (costs, clinical outcomes 
and quality of life), which means that the eﬀect of the 
co-occurring diseases is either more or less than could 
be expected from their individual eﬀects. In detail, the 
typical multimorbidity cluster in diabetes patients is char-
acterized by one or more of the following diabetes-related 
acute or chronic complications: coronary heart disease 
(CHD), chronic heart failure (CHF), stroke, retinopathy, 
renal insuﬃciency, and peripheral vascular disease [4]. It 
is to be expected that the coexistence of multiple diseases 
will be a major contributing factor to the increasing eco-
nomic burden of diabetes, which is currently estimated 
at US$1.3 trillion worldwide [5]. Therefore, to conduct 
thorough health economic evaluations of new diabetes and 
complication treatments or prevention programs, diabe-
tes models that consider complex interaction patterns are 
becoming increasingly important. Two of the best known 
non-commercial international type 2 diabetes models are 
the UK Prospective Diabetes Study (UKPDS) model and 
the model developed by the Center for Disease Control 
and Prevention/Research Triangle Institute (CDC/RTI) [6, 
7]. For example, the CDC/RTI model uses ﬁve individual 
disease paths for the most common complications and 
integrates their interactions through a faster progression 
on these paths (e.g., presence of hypertensive nephropathy 
leads to faster progression of chronic heart disease com-
pared to the absence of nephropathy). As another exam-
ple, a study of UKPDS data found no signiﬁcant eﬀect of 
the co-occurrence of complications on patient’s quality 
of life [8], whereas a German study showed that patients 
with diabetes, coronary events, and a history of stroke had 
a worse quality of life than could be expected from the 
separate eﬀects [9]. However, there are only limited data 
and evidence to inform diabetes models about the eco-
nomic consequences of disease interactions [10]. Due to 
their special focus and time- and budget-restricted nature, 
randomized trials, if they investigate interactions at all, 
generally concentrate on interactions between frequent 
outcomes. Moreover, in Germany, data sources such as 
routinely collected statutory health insurance (SHI) data 
may be better suited because of their large sample size, 
extensive population coverage (around 90%), and detailed 
cost data over several years [11].
The primary aim of this study was to use a large claims 
data set to explore regression-based strategies for analyz-
ing the economic impact of multiple type 2 diabetes-related 
complications and their interactions on total costs. A second-
ary purpose of this study is to describe the patterns of these 
disease interactions. This study builds on a previous study, 
where we presented the data together with a longitudinal 
analysis of quarterly costs for incident complications, but 
without considering interactions [12]. In addition to present-
ing new empirical evidence for Germany, this study has a 
strong methodological focus that addresses data accuracy 
issues and diﬀerentiates between the co-occurrence of preva-
lent complications or disease groups and the development 
of incident complications on top of prevalent complications. 
Our methodology and ﬁndings will serve as an important 
input for data scientists, and especially developers of diabe-
tes and related models.
2  Methods
2.1  Data and Research Design
A core component of Germany’s healthcare system is its 
SHI, covering ~ 90% of the population. This retrospective 
cohort study is based on data from the largest SHI provider 
in Germany, the Techniker Krankenkasse (TK), which 
included around 10 million insured people in 2017. In addi-
tion to basic demographic data, the claims contain detailed 
information on, for example, healthcare costs, outpatient and 
inpatient diagnoses and procedures, and medication data. 
Although outpatient diagnoses are only documented on a 
quarterly level, admission and discharge dates are available 
for inpatient data. The selection of type 2 diabetes patients 
was deﬁned on the basis of two outpatient diagnoses in two 
diﬀerent quarters and/or one inpatient diagnosis (Interna-
tional Statistical Classiﬁcation of Diseases and Related 
Health Problems, 10th revision, German Modiﬁcation [ICD-
10-GM] codes E11 and E14), prescription of oral antidiabet-
ics, and participation in a disease management program for 
type 2 diabetes. All patients who met the inclusion criteria 
and passed the exclusion criteria in the baseline year (2012) 
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were included in the analysis. Full details on the iterative 
selection algorithm were published recently [12] (a sum-
mary can be found in the electronic supplementary mate-
rial; see “Supplementary Appendix I” on the “selection of 
study population”). The follow-up period of this study cov-
ered 3 years, from 2013 to 2015, so that every person had 
up to three observations, one for each calendar year. The 
whole time horizon is 4 years, because outpatient service 
data are only stored for a limited time, according to social 
laws. Healthcare costs include outpatient and inpatient ser-
vices, medication, rehabilitation, and the provision of aids 
and appliances. All costs are expressed in 2015 euros using 
oﬃcial inﬂation data from the Federal Statistical Oﬃce (14).
2.2  Choice and Identiﬁcation of Prevalent 
and Incident Complications
The following complications were considered and are char-
acteristically used in diabetes models, such as the CDC/RTI 
model and the UKPDS outcomes model: macrovascular 
complications, including angina pectoris, CHF, MI/car-
diac arrest (CA), stroke, and other ischemic heart diseases 
(IHD), and microvascular complications including retinopa-
thy, blindness, diabetic foot, lower extremity amputation, 
nephropathy, and end-stage renal disease (ESRD). All these 
complications are known to belong to the most common 
comorbidity clusters among patients with diabetes [4]. The 
complications were identiﬁed based on ICD diagnoses and 
outpatient and inpatient procedure codes (see Table S1 in the 
electronic supplementary material or the previous publica-
tion) [12]. A distinction can be made between prevalent and 
incident complications in order to address diﬀerent research 
aspects (descriptive and causal). The deﬁnition of prevalent 
complications required that at least one outpatient or one pri-
mary or secondary inpatient ICD diagnosis was documented 
in a speciﬁc year at baseline or follow-up [12]. Uncertain 
diagnoses were not considered. In the case of acute mac-
rovascular complications (MI/CA, stroke, and IHD), only 
hospitalizations with a primary diagnosis were considered. 
On the other hand, the deﬁnition of incident complications 
additionally required that patients were free from diagnoses 
of the disease at baseline (2012). Otherwise, patients were 
deﬁned as having a prevalent history of the complication, 
which was assumed to continue throughout the follow-up.
2.3  Strategies to Address Diabetes-Related 
Multimorbidity and Interactions
Figure S1 (see the electronic supplementary material) shows 
important analytical aspects of multimorbidity, including the 
type of measurement, chronology of diseases, diﬀerentia-
tion between diabetes-related complications and unrelated 
comorbidities, eﬀect of interactions, and subgroup eﬀects. 
As this study focuses on diabetes-related multimorbidity, 
four diﬀerent strategies were explored to develop a compre-
hensive yet granular understanding of the economic eﬀect of 
co-occurring complications and their speciﬁc interactions. 
Before looking at speciﬁc pairwise interactions, we start 
with the most common method in the literature to indicate 
whether the presence of multimorbidity is associated with 
higher costs.
• Strategy 1 evaluates diabetes-related multimorbidity by 
simply counting multiple prevalent complications (i.e., 
two, three, or more complications). It makes the assump-
tion of independence of the type of complication and is 
helpful for comparison reasons.
To add complexity, the next two strategies considered 
interactions between groups of prevalent complications or 
single prevalent complications in each year.
• Strategy 2 divides the spectrum of complications into two 
main pathophysiological groups (microvascular and mac-
rovascular) without looking at the relationship between 
speciﬁc complications [13].
• Strategy 3 looks at speciﬁc interactions of prevalent com-
plications (e.g., between present retinopathy and diabetic 
foot).
Finally, the last strategy helps to understand the possible 
chronological dependence structure of diabetes-related mul-
timorbidity and temporal causality of interactions.
• Strategy 4 distinguishes between chronic complications 
that were present since baseline and incident compli-
cations that started or occurred in the follow-up (e.g., 
prevalent CHF since baseline and incident MI in the 
follow-up). Interactions between prevalent and incident 
complications are referred to as sequential interactions.
2.4  Data Accuracy and Interaction Patterns 
Emerging from the Data
There are two important issues arising from the data that 
we have to address in this study of the inﬂuence of interac-
tion patterns on healthcare costs. The ﬁrst is that we have 
to decide whether diﬀerent stages of the same disease in a 
given time period contribute to multimorbidity. The second 
is that claims data by nature only reﬂect real-world clinical 
practice records; to improve data accuracy, it can be neces-
sary to correct irregular diagnostic patterns of chronic dis-
eases. On the ﬁrst point, in the annual cross-sectional data, 
there is a strong correlation between ESRD and nephropathy, 
amputation and foot complications, and blindness and retin-
opathy, which practically means that the majority of patients 
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with ESRD, amputation, or blindness were also diagnosed 
with the earlier stages of the complication in the same year 
(but not vice versa). This is not surprising as it reﬂects the 
natural progression of complications, e.g., a foot ulcer nor-
mally precedes an amputation. Similarly, in a Markov model 
setting, patients are always modeled as transitioning from 
an early to an advanced stage. In order to avoid a multimor-
bidity problem between conditions of the same complica-
tion family, we applied this perspective and considered the 
advanced stage of a complication (ESRD, blindness, ampu-
tation) in years with two competing diagnoses. On the sec-
ond point, in the longitudinal view, there can be gaps in the 
diagnostic validity of chronic complications (retinopathy/
blindness, nephropathy/ESRD, CHF, angina pectoris, dia-
betic foot) resulting from incomplete coding of diagnoses 
by physicians and irregular visits to the doctor (see Table S2 
in the electronic supplementary material). For example, a 
chronic diagnosis was recorded in 2013 and 2015, but was 
missing in 2014. These types of gaps of one or more years 
can be interpreted as possible missing information, which 
can inﬂuence the analysis of interaction patterns. We there-
fore examined the eﬀect of diﬀerent algorithms to impute for 
such possible missing diagnoses (details on the imputation 
routine and our rationales can be found in “Supplementary 
Appendix II” in the electronic supplementary material). It 
was decided, based on preliminary regression analyses of the 
observed and imputed data, to correct for missing diagnoses 
in the chronic history of diabetic foot and retinopathy. For 
all other conditions, the original diagnoses data were used.
2.5  Statistical Analysis
To account for the non-independence of observations within 
each subject, we used a generalized estimating equations 
(GEE) model with a first-order autocorrelation struc-
ture (AR(1)). A near normality of the sample means was 
assumed. This assumption is justiﬁed by literature recom-
mendations, based on the large sample size and the relatively 
low proportion of zero costs (< 2%) [14]. In addition, the 
additive approach has been veriﬁed to provide a better model 
ﬁt based on the mean square error compared with a multi-
plicative model with a gamma log-link GEE model where 
€1 was assigned for patients with zero costs. Strategies 1–3 
are based on a prevalence approach, which leads to the fol-
lowing set of variables (see “Statistical Appendix” in the 
electronic supplementary material for full model notation): 
age (in ﬁve age groups), sex, age–sex interaction, presence 
of diﬀerent complications, plus the number of complications 
or interactions (according to the strategy). Strategy 4 leads 
to the extended set of the following variables: age groups, 
sex, age–sex interaction, occurrence of diﬀerent incident 
complications, presence of prevalent chronic complications 
at baseline, plus sequential interactions. For strategies 3 
and 4, which require careful variable selection, interactions 
were included using a stepwise approach based on a p value 
of 0.05 [15]. All analyses were performed at the Scientiﬁc 
Institute of TK for Beneﬁt and Eﬃciency in Health Care 
(WINEG) that approved the intended use of the data.
3  Results
3.1  Sample Characteristics
The study sample included 316,220 patients with a mean 
age of ~ 66 years; over 60% of them were men. The baseline 
characteristics in Table 1 provide a ﬁrst indication that mul-
timorbidity is associated with diﬀerent population character-
istics. Out of the total population, 61% had no complications 
at baseline, 26% had one complication, and 13% had at least 
two or more complications. It was found that the proportion 
of men rises with the number of complications (~ 69% in the 
group with at least two complications). Similarly, the mean 
age and share of participants in a structured disease manage-
ment program for type 2 diabetes is the highest in this group, 
with over 72% and approximately 72 years. The proportion 
of patients receiving no antidiabetic treatment was maxi-
mal (~ 42%) in the group with no complications, whereas 
the proportion of an insulin-based therapy (insulin only or 
combined with oral agents) is highest in the group with two 
or more complications (~ 35%). Regarding other comorbidi-
ties and risk factors, hypertension is the most frequent, with 
around 98% in the group with two or more complications 
compared with the overall average of ~ 86%.
3.2  Descriptive Analysis
Figure 1 shows what the diabetes-related multimorbidity 
network looks like in this population. The 3-year preva-
lence rates of the complications (2013–2015) are mapped 
as well as the most frequent interactions between diﬀerent 
types of complications. Further details on the frequencies 
of interactions can be found in Table S3 (see the electronic 
supplementary material). We did not include hypertension 
because the majority already had diagnosed hypertension 
or received antihypertensive agents. Nephropathy (~ 28%), 
CHF (~ 23%), and foot complications (22%) had the highest 
3-year prevalence. Owing to the higher frequency, the co-
occurrence of these conditions is also more likely. Nephrop-
athy and CHF is the most frequent interaction (41% of CHF 
observations), followed by nephropathy and foot complica-
tions (37% of diabetic foot observations), and retinopathy 
and foot complications (25% of retinopathy observations). 
It is also noticeable that most cardio- and cerebrovascular 
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conditions are likely to appear together with nephropathy 
and CHF.
3.3  Regression Analysis
Tables 2 and 3 show the results for strategies 1–3 that are 
based on a cross-sectional prevalence approach. Depend-
ing on the strategy used, prevalent complications were 
associated with the following additional costs per year 
(compared with a population without complications): 
diabetic foot €1100–1300, amputation €18,200–20,600, 
retinopathy –€200 to over €200, blindness €1800–2100, 
nephropathy €2500–2600, ESRD €26,000–30,000, stroke 
€12,300–13,000, MI €6800–7700, IHD €5700–6800, angina 
pectoris €1000–1700, and CHF €2500–3200. In strategy 1 
(Table 2), we can only see that the number of complications 
(2, 3, and ≥ 4) has a signiﬁcant impact on total costs. The 
implementation of more advanced strategies is needed to 
interpret speciﬁc interaction eﬀects. In strategy 2 (Table 3), 
we gain more information on the relevance of pathophysi-
ological groups of complications (microvascular and macro-
vascular). Although the presence of multiple microvascular 
complications showed a negative eﬀect on total costs (par-
ticularly to correct for the overestimation of inpatient costs), 
multiple macrovascular complications  or interactions 
between micro- and macrovascular complications were posi-
tively associated with total costs. In addition, the size of the 
eﬀect signiﬁcantly depends on the number of micro- or mac-
rovascular complications. In strategy 3, we extensively ana-
lyzed speciﬁc disease–disease interactions of prevalent con-
ditions. Out of 52 possible interactions, 13 interactions had a 
signiﬁcant impact on total costs. CHF has been shown to be 
of particular importance in the pairwise interactions (espe-
cially for cardiovascular conditions, but also for microvas-
cular complications). Most of the interactions had a positive 
eﬀect on total costs, ranging from approximately €180 for 
retinopathy and diabetic foot to around €13,600 for ESRD 
and IHD. Negative eﬀects on total costs were found for cer-
tain interactions with retinopathy and angina pectoris. As 
an indicator for the economic relevance of speciﬁc interac-
tions, Table S4 (see the electronic supplementary material) 
shows the relative proportions of interaction estimates to the 
mean estimates of complications. Generally, the percentage 
is far over 10%, indicating a moderate to high relevance. In 
Table 1  Baseline characteristics in 2012, stratiﬁed by number of known diabetes-related complications
The following complications were considered: retinopathy, blindness, diabetic foot, amputation, nephropathy, ESRD, angina, CHF, MI, stroke, 
and IHD. There is no overlap between retinopathy and blindness, nephropathy and ESRD, and foot and amputation
aDCSI adapted Diabetes Complications Severity Index, ATC Anatomical Therapeutic Chemical Classiﬁcation System, CHF chronic heart fail-
ure, DMP disease management program, ESRD end-stage renal disease, ICD International Classiﬁcation of Diseases, IHD (other) ischemic heart 
disease, MI myocardial infarction
Overall 
(n = 316,220)
No complications at 
baseline (n = 193,166)
One complication 
(n = 82,360)
At least two 
complications 
(n = 40,694)
Participation in the DMP for type 2 diabetes (%) 61.2 56.7 66.3 72.1
Sex, male (%) 63.3 61.7 64.4 68.9
Mean age (years) 65.9 63.4 68.1 71.6
Age group (%)
 < 50 years 8.6 11.5 4.9 1.9
 50–59 years 19.4 23.5 15.0 9.0
 60–69 years 29.6 31.0 29.1 24.1
 70–79 years 32.4 27.5 38.2 44.3
 > 80 years 10.0 6.4 12.9 20.8
Type of antidiabetic treatment (%)
 No antidiabetics 37.9 41.7 34.4 27.1
 Only oral 47.4 49.0 47.9 38.5
 Oral + insulin 9.2 6.4 11.4 18.2
 Only insulin 5.5 2.9 6.4 16.3
Mean aDCSI score 1.7 0.9 2.4 4.4
Other comorbidities (%)
 Hypertension (ICD codes I10–I15 or ATC C02–C09) 85.8 80.1 93.0 98.1
 Depression (F32–F32 or ATC N06A) 22.6 21.0 23.6 27.8
 Obesity (E66) 30.1 27.5 31.8 38.9
 Malignant cancer (C00–C97) 14.7 12.2 17.3 21.3
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strategy 4 (Table 4), the sequence of speciﬁc disease–dis-
ease interactions was assessed using an incidence approach. 
Annual costs for incident complications ranged from €40 
for retinopathy to around €26,000 for ESRD. Out of 60 pos-
sible interactions, 15 sequential interactions were found to 
have a signiﬁcant impact on total costs. Again, history of 
CHF followed by ESRD was frequently involved in positive 
interactions. In some interactions, a history of retinopathy, 
diabetic foot, or angina pectoris led to a negative eﬀect on 
total costs. Switching incident and historical conditions led 
to either reversed eﬀects (from positive to negative and vice 
versa) or positive but smaller eﬀects. Although not all these 
interactions were signiﬁcant in the overall model, it indicates 
that the chronology of diseases is important.  
4  Discussion
This study provides novel methodological and empirical 
ﬁndings on the assessment of the economic impact of multi-
ple diabetes-related complications and their interactions. At 
an empirical level, there is currently no other German study 
providing similarly detailed cost information on model-
relevant diabetes complications. At a methodological level, 
there is no international study exploring the economic 
eﬀect of interactions between multiple disease complica-
tions in a comparably structured way. Methodology and 
results on interaction patterns and economic eﬀects can 
be used to inform other research in diabetes, especially 
health economic models or even to build a German diabe-
tes model. The results of the regression models gradually 
revealed the complexity of diabetes-related multimorbid-
ity that goes beyond the simple counting of comorbidi-
ties/complications. In detail, this study adds additional 
evidence for diabetes models, indicating that the eﬀect of 
diabetes-related multimorbidity is less than multiplicative 
yet more than additive. In support of this, we systematically 
identiﬁed signiﬁcant interactions between disease groups 
and single complications based on additive GEE models, 
where the interactions predominantly had a positive eﬀect 
on total healthcare costs. Some of the interactions (such 
as nephropathy and CHF) had already been identiﬁed to 
be epidemiologically important based on a multimorbid-
ity network. Apart from highly prevalent complications, 
expensive conditions (such as amputations) were also 
found to be more sensitive for interactions. In addition, 
the sequence of the occurrence of complications revealed 
an additional impact on the interpretation of interactions.
Fig. 1  Multimorbidity network based on most important type 2 dia-
betes complications. The bubble size corresponds to the 3-year 
prevalence of ever having the disease in 2013–2015, and should take 
account of the visibility of rare complications. For reasons of clar-
ity and to avoid unnecessary complexity, all disease pairings with 
more than 10,000 observations are shown. In the case of less frequent 
diseases (ESRD, IHD, MI, stroke, blindness), the two most common 
combinations are presented. The thickness of the lines therefore cor-
responds to the relative frequency (with the most frequent pair, CHF 
and nephropathy, as reference). The relative position of the bubbles is 
not speciﬁed and is mainly a result of better visibility and grouping of 
similar micro- and macrovascular complications. CHF chronic heart 
failure, ESRD end-stage renal disease, IHD (other) ischemic heart 
disease, MI myocardial infarction, obs observations
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4.1  Comparison and Cross-Validation with Other 
Studies
Direct evidence on the economic impact of diabetes-related 
multimorbidity, speciﬁcally on disease–disease interactions, 
is barely available. Although there is some international 
evidence indicating that costs increase gradually with the 
number of comorbidities/complications and higher levels of 
the adapted Diabetes Complications Severity Index (aDCSI) 
[16, 17], detailed studies on speciﬁc interactions are lacking. 
In addition, there is a study that showed higher hospitaliza-
tion costs for type 2 diabetes resulting from macrovascular 
rather than microvascular complications; however, it did 
not consider a combination of both [18]. Regarding spe-
ciﬁc interactions, epidemiological literature was found on 
associations between diabetic foot and retinopathy [19], 
amputation and chronic kidney disease [20, 21], retinopathy 
and chronic kidney disease [22, 23], chronic kidney disease 
and cardiovascular disease [24–26], and diabetic foot and 
cardio- and cerebrovascular diseases [27, 28]. Interactions 
were often reﬂected in increased severity and faster progres-
sion to more advanced stages or death. In addition, these 
studies support the involvement of microvascular diseases 
in the development of macrovascular diseases in patients 
with diabetes.
4.2  Interpretation and Integration of Interactions 
in Diabetes Models
An important point for discussion is the challenge of 
integrating evidence on multimorbidity in diabetes simu-
lation models. Modeling a heterogeneous population of 
patients with a systemic disease and multiple complica-
tions is challenging since a complex network of patient 
characteristics, pathophysiological processes, and dif-
ferent treatment approaches have to be translated into a 
formal computer simulation [29]. Diabetes is one of the 
few examples of whole disease models, where multiple 
comorbidities are modeled simultaneously (e.g., using a 
summarized state transition matrix as in the CDC/RTI 
model) [30]. Although these models by nature focus on 
well-known diabetes-related complications, they are con-
stantly updated as soon as new evidence emerges. In these 
complex structures, multimorbidity is often taken into 
account by including covariates (e.g., blood pressure) that 
have multiple effects and can thus cause interactions. The 
most common interactions are usually two-way disease 
interactions that lead to a faster progression on each of the 
disease paths. The detailed analysis of specific disease-
disease interactions in this study is of particular interest 
for cost-effectiveness analyses based on microsimulation 
models, as the prediction of costs in patients with specific 
complications can be improved. Markov cohort models, 
in contrast, are more focused on population mean costs 
of complications rather than on individual variations due 
to interactions. In particular, such methods and find-
ings can be used to refine interaction patterns and assign 
detailed cost information to specific health states. In this 
context, the following assumptions and constraints have 
to be considered. First, the exact lapse of time between 
two co-occurring conditions cannot be determined; how-
ever, most of the complications are chronic, and diabe-
tes models typically use 1-year intervals. Second, we do 
not account for the longitudinal development of disease 
interactions; however, at least in strategy 4, we were still 
Table 2  Eﬀects of prevalent type 2 diabetes complications and the 
number of complications on total costs per year in GEE normal 
regression (strategy 1)
CHF chronic heart failure, ESRD end-stage renal disease, GEE gen-
eralized estimating equations, IHD (other) ischemic heart disease, MI 
myocardial infarction, Ref. reference, SE standard error
*p < 0.05; **p < 0.01; ***p < 0.001
a Includes intercept, weighted age- and sex-speciﬁc estimates, and 
interaction between age groups and sex (see “Statistical Appendix” in 
the electronic supplementary material for full model notation)
b The following complications were considered: retinopathy, blind-
ness, diabetic foot, amputation, nephropathy, ESRD, angina, CHF, 
MI, stroke, and IHD
Variable Strategy 1
Basic set, estimate (SE), €
Population-average constant (no complications)a 2893
Complication/condition (Ref. = no)
 Diabetic foot 1118*** (42)
 Amputation 20,352*** (676)
 Retinopathy − 179*** (33)
 Blindness 1799*** (176)
 Nephropathy 2542*** (43)
 ESRD 29,693*** (526)
 Stroke 12,648*** (259)
 MI 7694*** (238)
 IHD 6788*** (193)
 Angina 1334*** (69)
 CHF 3160*** (49)
 Death 6396*** (162)
Multimorbidity measure
Number of  complicationsb, estimate (SE), €
 2 296*** (58)
 3 1126*** (108)
 ≥ 4 2618*** (197)
R-squared, %
With adjustment for main eﬀects of complications 
(reference case)
22.0
Without adjustment for main eﬀects of complica-
tions (count = 1, 2, 3, ≥ 4)
12.2
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Table 4  Eﬀects of incident type 2 diabetes complications in addition to prevalent chronic complications (at baseline) on total costs per year in 
GEE normal regression (strategy 4)
Variable Strategy 4
Basic set, estimate (SE), €
Population-average constant (no complications)a 2653
Complication/condition (Ref. = no)
 Diabetic foot 993*** (53)
 Amputation 14,489*** (531)
 Retinopathy 41 (44)
 Blindness 2529*** (242)
 Nephropathy 2920*** (57)
 ESRD 25,921 *** (663)
 Stroke 9347*** (223)
 MI 5219*** (191)
 IHD 3935*** (162)
 Angina 1362*** (78)
 CHF 3998*** (71)
 Death 6529*** (165)
History in 2012 (Ref. = no)
 Diabetic foot 1385*** (54)
 Amputation 6450*** (621)
 Retinopathy 292*** (38)
 Blindness 734*** (194)
 Nephropathy 1439*** (47)
 ESRD 23,875*** (660)
 Stroke 2284*** (180)
 MI 111 (174)
 IHD 2072 (99)
 Angina 107 (76)
 CHF 1682*** (53)
Multimorbidity measure Chronological occurrence
Interactions, estimate (SE), €
Diabetic foot (history) × stroke (incident) –1534** (577)
Angina (history) × CHF (incident) − 571* (266)
Retinopathy (history) × diabetic foot (incident) − 295* (117)
Nephropathy (history) × diabetic foot (incident) 644*** (147)
CHF (history) × nephropathy (incident) 881*** (159)
CHF (history) × diabetic foot (incident) 971*** (179)
CHF (history) × angina (incident) 1137*** (249)
CHF (history) ×   IHD (incident) 1486* (622)
Diabetic foot (history) × IHD (incident) 1844 (749)
CHF (history) × amputation (incident) 2860* (1390)
ESRD (history) × diabetic foot (incident) 3176* (1502)
ESRD (history) × CHF (incident) 3720** (1350)
Amputation (history) × CHF (incident) 4592* (2240)
Amputation (history) × blindness (incident) 10,459* (5120)
ESRD (history) × IHD (incident) 12,257*** (3661)
R-squared (%) 19.7
∆QICu (compared to strategy 1)b 23
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able to integrate a time component in our analysis. In 
detail, most of the significant disease–disease interac-
tions (strategy 3 and 4) were positively associated with 
higher costs. This can be due to several factors: causal 
interactions within the pathogenesis, severity, disease 
management, or progression (i.e., more severe in combi-
nation with renal failure, less severe in combination with 
retinopathy). These factors, however, do not change the 
interpretation of the economic effect of the interactions. 
Although positive interactions are often easier to inter-
pret, it has to be considered for negative interactions that 
certain costs may be covered in the main estimates, so 
that negative interactions reduce double counting of costs. 
One reason for possible double counting is that total cost 
estimates include inpatient costs for hospital admissions 
due to primary and other (secondary) diagnoses (e.g., 
CHF and retinopathy). In addition, negative interactions 
are influenced by the severity of complications that can 
be different depending on the presence of early stages of 
other conditions (e.g., CHF with concurrent retinopathy 
may be less severe than average CHF). Beyond the inter-
pretation of the direction of interactions (positive or nega-
tive), it is important to understand the economic relevance 
of specific disease interactions. Our study could show that 
just counting complications (strategy 1) is not sufficient 
to dissect and quantify potential interactions within multi-
morbidity. In the example of two complications, estimated 
additional costs were relatively low because all types of 
complications and their (significant and non-significant) 
interactions are mixed up in one estimate. Therefore, the 
usefulness of a model strategy is not only a question of 
the goodness-of-fit, but highly depends on the intended 
purpose of analysis (e.g., as adjustment variable for pre-
diction, or to investigate the underlying effects of diabe-
tes-related multimorbidity).
4.3  Further Strengths and Weaknesses of this Study
Among the core strengths of this study is its large popula-
tion size that is less vulnerable to outliers. The analysis 
was based on real-world data from a nationwide health 
insurance fund that can be regarded as the best available 
data source for healthcare costs in Germany. However, 
some limitations must be considered. These include a 
lack of clinical data (e.g., severity), unknown duration of 
diabetes, and reliance on diagnostic accuracy. Beyond the 
mere comparison of sensitivity and speciﬁcity of disease 
deﬁnitions over multiple years in the literature [31], we 
were able to specify the incomplete patterns of diagnoses 
and proposed a way to handle this issue in claims data. In 
addition, several factors can explain diagnoses restricted 
to 1 year, including acute episodes of chronic conditions, 
accidental ﬁndings, remissions, or false-positive cases. 
Another key feature of this study is our eﬀort to inform 
health economic diabetes models. Therefore, and to avoid 
an overﬁtting of the model, we did not adjust for other 
comorbidities than model-relevant complications. In addi-
tion, the included complications have been shown to make 
up the most important comorbidity clusters [4]. The excep-
tion is that we did not adjust for hypertension, because 
the vast majority of patients already had diagnosed/treated 
hypertension at baseline. Finally, it is important that this 
study primarily provides information on statistical cost 
interactions and can only touch upon the issue of causal 
interactions. Despite there being more to be done, these 
ﬁndings provide a broad basis for discussion and further 
research investigations in this area.
5  Future Implications
The results of this study have several implications for diﬀer-
ent healthcare stakeholders. From a modeler’s perspective, 
future diabetes models should pay more attention to com-
puting multimorbidity, and especially interactions, which 
may have a considerable eﬀect on both health eﬀects and 
costs. From a policy perspective, our ﬁndings encourage the 
implementation and further development of more integrated 
prevention and disease management programs that take bet-
ter account of preexisting or co-occurring conditions. At 
the same time, a complete clinical/epidemiological view 
requires further observational studies to unravel the complex 
interplay between multiple shared pathogenic mechanisms 
of diabetes and its complications.
Data Availability Statement The data are owned by the 
Techniker Krankenkasse. To fulﬁll the legal requirements 
to obtain the data, researchers must obtain permission 
AIC Akaike information criterion, CHF chronic heart failure, ESRD end-stage renal disease, GEE generalized estimating equations, IHD (other) 
ischemic heart disease, MI myocardial infarction, QIC quasi information criterion, Ref. reference, SE standard error
*p < 0.05; **p < 0.01; ***p < 0.001
a Includes intercept, weighted age- and sex-speciﬁc estimates, and interaction between age groups and sex (see “Statistical Appendix” in the elec-
tronic supplementary material for full model notation)
b The QIC is an adaptation of the AIC in GEE models. Whereas individual QIC values are not interpretable, their diﬀerences (deltas) indicate a 
more or less parsimonious model (higher is less parsimonious)
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for a speciﬁc research question from the German Fed-
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must conclude a contract with the statutory health insurer 
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by the data protection oﬃcer both at the statutory health 
insurer and the research institute as well as the local ethics 
committee.
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2 
I. Selection of study population 
 
The first step was to identify patients who had at least one outpatient or inpatient type 2 
(ICD-10 E11) or unspecified diagnosis (E14) in the baseline year, 2012, without other 
diagnoses of gestational diabetes (O24), pancreoprive diabetes (E13), or pancreatic 
carcinoma (C25). At the end of step 1, a total of 441,829 potential type 2 diabetes patients 
were identified. Further exclusion criteria were applied in subsequent steps:  age <18 years 
(2,432 patients excluded), insufficient diagnoses (68,578), unclear type 1 diabetes (30,282), 
participation in a disease management program for type 1 diabetes (1,445), end of insurance 
in 2012 (due to death or other reasons) (12,228), lack of full insurance history in the follow-up 
period 2013-2015 (except death) (4,950), unknown residence or residence abroad (699), and 
inconsistent or implausible diabetes cases (4,995). Insufficient/uncertain type 2 diabetes 
diagnosis was supposed when a patient had less than two outpatient diagnoses in separate 
quarters, only unspecified diabetes diagnoses (E14), or a competing type 1 diagnosis (E10). 
In these cases, we considered additional criteria, including the prescription of oral 
antidiabetics or the participation in a disease management program for type 2 diabetes. The 
final population consisted of 316,220 patients. 
For a figure of the selection algorithm, please additionally see Kähm et al. 2018 [1].  
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3 
II. Data validation: Imputation of missing values in the diagnostic course of chronic 
complications 
 
Patients with continuously higher costs are relevant, even without showing the diagnosis in 
every year (e.g., incomplete coding of diagnoses by physicians, irregular visits to the doctor).  
Information on the successful treatment and cure of diseases is not directly available from 
claims data, and derivatives of the likelihood are difficult to analyze considering the diversity 
of complications and the available period of 4 years.  
Therefore, we examined the effect of different algorithms to impute for possible missing 
diagnosis information (see Table S1) by including separate variables for observed and 
imputed data in the regression and comparing the similarity of the cost estimates. Since 
corrections to diagnoses can only be performed prospectively from the first diagnosis 
onward, we tested the following consecutive strategies:  
 First, a missing diagnosis in 1 year is corrected (e.g., diagnosis was recorded in 2013 
and 2015, but was missing in 2014).  
 Second, missing diagnoses in up to 2 consecutive years are corrected (diagnosis was 
recorded in 2012 and 2015, but was missing in 2013 and 2014).  
 Third, in addition to the last point, the disease is assumed to continue until death or 
the end of the study for patients with two consecutive years of disease.  
Preliminary regression analyses of the observed and imputed diagnostic data showed no 
significant difference in the estimated costs for observed and imputed diabetic foot or 
observed and imputed retinopathy based on all three imputation algorithms (e.g., 95% 
confidence intervals for imputed diabetic foot €1231 [€768, €1693] and observed diabetic 
foot €1435 [€1359, €1511]). Therefore, diagnostic gaps for these two conditions were 
imputed according to the last strategy. For all other conditions, the original diagnoses data 
were used. 
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4 
III. Statistical appendix 
 
The basic regression model for strategy 1 is noted as follows*: 
yij = β0 + β1Z1i + β2lZ2il + β3lZ1iZ2il + β4kZ4ijk +β5Z5ij+ β6mZ2ijm+ eij 
 
where: 
i = patient i  
j = observation j (year 2013–2015) 
k = complication k (diabetic foot/amputation, retinopathy/blindness, nephropathy/ESRD, MI, 
CHF, stroke, IHD, angina pectoris)  
l = age group l 
m = number of complications 
 
yij =  outcome/total healthcare costs for patient i and observation j  
β0  = coefficient for the intercept 
 
β1 = coefficient for sex 
Z1i = dummy variable for sex (0=“female”, 1=“male”) 
 
β2l = coefficient for age group l  
Z2il = dummy variables for the age group  
(l=1:  “<50”=1,else 0 , 
l=2: “50–60”=1 else 0, 
l=3:  “60–70”=1 else 0,  
l=4:  “>80”=1 else 0) 
 
β3l = coefficient for interaction term of male sex and age group l  
 
β4k = coefficient for prevalent complication k 
Z4ijk = dummy variables for complication k: 1 if present, 0 otherwise 
 
β5= coefficient for death from other reasons  
Z5ij = 1 (for death from other reasons), 0 otherwise  
 
β6m = coefficient for number of complications m  
Z6ijm = dummy variables for the number of complications  
(m=2: 1, else 0 , 
m=3: 1, else 0, 
m≥4: 1, else 0) 
 
eij = error term for patient i, observation j  
 
* Strategies 2 and 3 build on the first strategy. Instead of the crude number of complications, interactions between 
micro- and macrovascular complications (strategy 2) and disease–disease interactions (strategy 3) are 
considered. No interactions within the same group of complication were considered. 
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The regression model for strategy 4 is different from the others and noted as follows: 
yij = β0 + β1Z1i + β2lZ2il + β3lZ1iZ2il + β4kZ4ik +β5Z5ij + β6kZ6ijk + β7kkZ4ikZ6ijk + eij 
 
where: 
i = patient i  
j = observation j (year 2013–2015) 
k = complication k (diabetic foot/amputation, retinopathy/blindness, nephropathy/ESRD, MI, 
CHF, stroke, IHD, angina pectoris) 
l = age group l 
 
yij =  outcome/total healthcare costs for patient i and observation j  
β0  = coefficient for the intercept 
 
β1 = coefficient for sex 
Z1i = dummy variable for sex (0=“female”, 1=“male”) 
 
β2l = coefficient for age group l  
Z2il = dummy variables for the age group  
(l=1:  “<50”=1,else 0 , 
l=2: “50–60”=1 else 0, 
l=3:  “60–70”=1 else 0,  
l=4:  “>80”=1 else 0) 
 
β3l = coefficient for interaction term of male sex and age group l  
 
β4k= coefficient for history of complication k in 2012 
Z4ik = for each complication k: 1 if present at baseline, 0 otherwise 
 
β5= coefficient for death from other reasons  
Z5ij = 1 (for death from other reasons), 0 otherwise  
 
β6k = coefficient for new complication k 
Z6ijk = dummy variables for new complication k: 1 with onset of the disease, 0 otherwise 
 
β7kk = coefficient for interaction between a history of prevalent complication k and incident 
complication k*  
 
eij = error term for patient i, observation j  
 
* No interactions within the same group of complication. In addition, only the history of chronic complications was 
considered (diabetic foot, retinopathy, blindness, nephropathy, end-stage renal disease, angina pectoris, chronic 
heart failure).  
 
Abbreviations: CHF, chronic heart failure; ESRD, end-stage renal disease; IHD, (other) ischemic heart disease; 
MI, myocardial infarction.  
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IV. Tables 
Table S1: Identification of relevant complications and events based on ICD-10-GM, OPS- 
and EBM-codes 
Microvascular complications ICD-, OPS- or EBM-codes 
Eye complications  
Retinopathy ICD-codes E10-E14.3- (diabetes with eye 
complications), H36.0 (diabetic retinopathy), 
H35.0 (background retinopathy and retinal 
vascular changes), H35.2 (other proliferative 
retinopathy) 
Blindness in one or two eyes ICD-codes H54.0 (blindness, both eyes), H54.4 
(blindness, one eye) 
Renal complications  
Renal insufficiency  E11.2- (or E14.2-) (diabetes with renal 
complications), ICD-codes N17 (acute renal 
failure), N18 (chronic renal failure, without N18.5), 
N19 (not other specified renal failure) 
ESRD  ICD-code N18.5 (terminal renal insufficiency) 
 with or without dialysis ICD-codes Z49 (dialysis), Z99.2 (long-term 
dialysis in renal insufficiency) 
OPS-codes 8-854 (hemodialysis), 8-855 
(hemodiafiltration), 8-857 (peritoneal dialysis), 8-
85a (dialysis after failed kidney transplant)  
EBM-codes 13602-13622 w/o 13621 (dialysis 
fees), 40815-40838 (material cost fee) 
Neuropathic complications  
Diabetic foot syndrome (with polyneuropathy and 
peripheral angiopathy) 
ICD-codes E10-E14.74 and .75 (diabetes with 
multiple complications, with diabetic foot 
syndrome)  
or 
ICD-code for peripheral neuropathy G63.2 
(diabetic polyneuropathy) + one of the ICD-codes 
for PVD: E11.5 (or E14.5) (diabetes with 
peripheral vascular complications), I70.2 
(atherosclerosis of extremities), I73.9 (peripheral 
vascular disease, not other specified), I79.2 
(diabetic peripheral angiopathy), R02 (gangrene)  
or 
EBM-code 02311 (treatment of diabetic foot) 
Amputation of lower extremities  OPS-codes 5-864 (amputation of lower extremity), 
5-865 (amputation of the foot) 
Macrovascular complications  
Cardiovascular complications  
Angina pectoris ICD-code I20 (angina pectoris) 
Chronic heart failure (CHF) ICD-codes I50 (heart failure) , I11.0 (hypertensive 
heart disease with heart failure), I13.0 
(hypertensive heart and chronic kidney disease 
with heart failure), I13.2 (Hypertensive heart and 
chronic kidney disease with heart failure and with 
end stage renal disease) 
Myocardial infarction/cardiac arrest  ICD-codes I21 (acute myocardial infarction), I46.0 
or .9 (cardiac arrest)  
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Other IHD  ICD-codes I22 (recurrent myocardial infarction), 
I24 (other acute ischemic heart disease), I25 
(chronic ischemic heart disease) 
Cerebrovascular complications  
Stroke*  ICD-codes I60 (subarachnoidal haemorrhage), I61 
(intracerebral bleeding), I62 (other non-traumatic 
intracranial bleeding), I63 (brain infarction), I64 
(stroke) 
Death  
All-cause death Reason for termination of membership due to 
death 
* Stroke includes bleeding inside the brain (hemorrhagic stroke).  
Abbreviations: CHF, chronic heart failure; EBM, uniform value scale for outpatient services; ESRD, end-stage 
renal disease; GM, german modification; ICD, International Classification of Diseases; IHD, ischemic heart 
disease; OPS, operation procedure codes; PVD, peripheral vascular disease. 
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Table S4: Strategy 3: Economic relevance of disease-disease interactions, expressed as the 
percentage of the main estimates  
Main estimates Estimate  
(in €) 
Lower 95% CI 
(in €)  
Upper 95% CI 
(in €) 
Diabetic Foot 1,294 1,216 1,372 
Amputation 18,248 16,978 19,517 
Retinopathy 242 182 301 
Blindness 2,119 1,775 2,463 
Nephropathy 2,454 2,371 2,537 
ESRD 25,731 24,413 27,048 
Stroke 13,085 12,580 13,590 
MI 6,829 6,378 7,281 
IHD 5,694 5,378 6,009 
Angina pectoris 1,703 1,588 1,818 
CHF 2,465 2,357 2,573 
    
Interactions Estimate  
(in €)/ in % 
Lower 95% CI 
(in €)/ in % 
Upper 95% CI 
(in €)/ in % 
Diabetic foot x retinopathy 183 22 343 
in % of diabetic foot 14% 2% 25% 
in % of retinopathy 76% 12% 114% 
Diabetic foot x CHF 554 320 788 
in % of diabetic foot 43% 26% 57% 
in % of CHF 22% 14% 31% 
Retinopathy x nephropathy -530 -693 -368 
in % of retinopathy -219% -380% -122% 
in % of nephropathy -22% -29% -14% 
Retinopathy x CHF -320 -537 -103 
in % of retinopathy -132% -294% -34% 
in % of CHF -13% -23% -4% 
Amputation x ESRD 8,923 1,530 16,315 
in % of amputation 49% 9% 84% 
in % of ESRD 35% 6% 60% 
Amputation x angina -5,282 -9,134 -1,430 
in % of amputation -29% -54% -7% 
in % of angina -310% -575% -79% 
Amputation x CHF 3,504 1,000 6,007 
in % of amputation 19% 6% 31% 
in % of CHF 142% 42% 233% 
Nephropathy x CHF 2,056 1,876 2,237 
in % of nephropathy 84% 79% 88% 
in % of CHF 83% 80% 87% 
ESRD x IHD 13,599 6,989 20,208 
in % of ESRD 53% 29% 75% 
in % of IHD 239% 130% 336% 
ESRD x CHF 6,982 5,136 8,829 
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in % of ESRD 27% 21% 33% 
in % of CHF 283% 218% 343% 
MI x CHF 2,298 1,443 3,154 
in % of MI 34% 23% 43% 
in % of CHF 93% 61% 123% 
IHD x CHF 2,286 1,636 2,936 
in % of IHD 40% 30% 49% 
in % of CHF 93% 69% 114% 
Angina x CHF 305 22 588 
in % of angina 18% 1% 32% 
in % of CHF 12% 1% 23% 
Abbreviations: CHF, chronic heart failure; CI, confidence interval; ESRD, end-stage renal disease; IHD (other) 
ischemic heart disease; MI, myocardial infarction.  
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V. Figures 
Figure S1: Essential analytical aspects of multimorbidity in type 2 diabetes patients [2-4] 
 
Abbreviations: aDCSI, adapted Diabetes Complications Severity Index; CCI, Charlson Comorbidity Index.  
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Figure S2: Descriptive analysis of the non-standardized total healthcare costs 2013–2015 by 
number of complications* and healthcare sector 
A. by sex 
 
B. by age groups 
 
 
* Number of complications was considered each year. Therefore, same patient can be counted in multiple 
categories.  
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